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Immediate versus delayed short-term integrated palliative care
for advanced long-term neurological conditions: the OPTCARE
Neuro RCT
Nilay Hepgul ,1 Rebecca Wilson ,1 Deokhee Yi ,1 Catherine Evans ,1,2
Sabrina Bajwah ,1 Vincent Crosby,3 Andrew Wilcock ,4 Fiona Lindsay ,5
Anthony Byrne ,6 Carolyn Young ,7 Karen Groves,8 Clare Smith ,9
Rachel Burman ,10 K Ray Chaudhuri ,11 Eli Silber ,12
Irene J Higginson 1* and Wei Gao 1* on behalf of OPTCARE Neuro
1Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation, King’s College London,
London, UK
2Sussex Community NHS Foundation Trust, Brighton, UK
3Department of Palliative Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK
4Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK
5Martlets Hospice, Hove, UK
6Marie Curie Palliative Care Research Centre, Cardiff University, Cardiff, UK
7Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK
8Queenscourt Hospice, Southport, UK
9Department of Palliative Care, Ashford and St. Peter’s Hospitals NHS Foundation Trust, Surrey, UK
10Department of Palliative Care, King’s College Hospital, London, UK
11National Parkinson Foundation Centre of Excellence, King’s College Hospital and King’s College
London, London, UK
12Department of Neurology, King’s College Hospital, London, UK
*Corresponding author wei.gao@kcl.ac.uk/irene.higginson@kcl.ac.uk
Background: Palliative care is recommended to help meet the needs of patients with progressive
non-cancer conditions, such as long-term neurological conditions. However, few trials have tested
palliative care in this population.
Objectives: To determine the effectiveness and cost-effectiveness of short-term integrated palliative
care in improving symptoms, improving patient- and caregiver-reported outcomes and reducing
hospital use for people severely affected by long-term neurological conditions.
Design: Pragmatic, randomised controlled, multicentre, fast-track trial, with an embedded qualitative
component and surveys.
Setting: Seven UK centres (South London, Nottingham, Liverpool, Cardiff, Brighton, Ashford and
Sheffield) with multiprofessional palliative care teams and neurology services.
Participants: People living with multiple sclerosis, idiopathic Parkinson’s disease, motor neurone
disease, multiple system atrophy or progressive supranuclear palsy, with unresolved symptoms and/or
complex psychosocial needs. The qualitative study involved patients, caregivers and health-care staff.
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Interventions: Participants were randomised to receive short-term integrated palliative care, delivered
by multiprofessional teams, immediately or after a 12-week wait (standard care group).
Main outcome measures: The primary outcome was a combined score of eight symptoms measured
by the Integrated Palliative care Outcome Scale for Neurological conditions 8 symptom subscale
(IPOS Neuro-S8) at 12 weeks. Secondary outcomes included patients’ other physical and psychological
symptoms, quality of life (EuroQol-5 Dimensions, five-level version), care satisfaction, caregiver burden,
service use and cost, and harms. Data were analysed using multiple imputation, generalised linear
mixed models, incremental cost-effectiveness ratios (threshold was the National Institute for Health
and Care Excellence £20,000 per quality-adjusted life-year) and cost-effectiveness planes. Qualitative
data were analysed thematically.
Results: We recruited 350 patients and 229 caregivers. There were no significant between-group
differences for primary or secondary outcomes. Patients receiving short-term integrated palliative care
had a significant improvement, from baseline to 12 weeks, on the primary outcome IPOS Neuro-S8
(–0.78, 95% confidence interval –1.29 to –0.26) and the secondary outcome of 24 physical symptoms
(–1.95, 99.55% confidence interval –3.60 to –0.30). This was not seen in the control group, in which
conversely, care satisfaction significantly reduced from baseline to 12 weeks (–2.89, 99.55% confidence
interval –5.19 to –0.59). Incremental cost-effectiveness ratios were smaller than the set threshold
(EuroQol-5 Dimensions index score –£23,545; IPOS Neuro-S8 –£1519), indicating that the
intervention provided cost savings plus better outcomes. Deaths, survival and hospitalisations were
similar between the two groups. Qualitative data suggested that the impact of the intervention
encompassed three themes: (1) adapting to losses and building resilience, (2) attending to function,
deficits and maintaining stability, and (3) enabling caregivers to care.
Conclusions: Our results indicate that short-term integrated palliative care provides improvements in
patient-reported physical symptoms at a lower cost and without harmful effects when compared with
standard care.
Limitations: Outcome measures may not have been sensitive enough to capture the multidimensional
changes from the intervention. Our surveys found that the control/standard and intervention services
were heterogeneous.
Future work: Refining short-term integrated palliative care and similar approaches for long-term
neurological conditions, focusing on better integration of existing services, criteria for referral and
research to improve symptom management.
Trial registration: Current Controlled Trials ISRCTN18337380.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Services
and Delivery Research programme and will be published in full in Health Services and Delivery Research;
Vol. 8, No. 36. See the NIHR Journals Library website for further project information.
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This study aimed to find out if short-term integrated palliative care altered symptoms or well-beingfor people living with long-term neurological conditions. It also studied the effects on their
caregivers and on health and social care costs.
People living with multiple sclerosis, idiopathic Parkinson’s disease, motor neurone disease, multiple
system atrophy or progressive supranuclear palsy, and with unresolved symptoms or complex needs,
were recruited into the study across seven UK centres. Participants were randomly assigned by chance
to receive either short-term integrated palliative care or standard care for 12 weeks. After 12 weeks,
the standard care group also received short-term integrated palliative care. The circumstances of
patients and caregivers in the two groups were compared at 12 weeks using questionnaires. A small
number of people were also invited to talk more about their experiences in an audio-recorded
interview. Health-care staff views were also sought through an online survey and focus groups.
A total of 350 patients and 229 caregivers were recruited. At 12 weeks there were no significant
differences between the two groups. However, patients receiving short-term integrated palliative
care showed an improvement from baseline to 12 weeks for several physical symptoms. The costs of
care were also lower and there were no harmful effects, compared with standard care. Conversely,
in the standard care group, care satisfaction lowered from baseline to 12 weeks. The in-depth
interviews showed that the impact of short-term integrated palliative care encompassed three themes:
(1) adapting to losses and building resilience, (2) attending to function, deficits and maintaining stability
and (3) enabling caregivers to care.
Our results suggest that short-term palliative care confers more benefits than harm and costs less
than standard care. Future research should focus on refining palliative care approaches for long-term
neurological conditions, including better integration between neurology and palliative care, and
improving the management of symptoms.
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The primary objective was to determine the clinical effectiveness and cost-effectiveness of short-term
integrated palliative care for people severely affected by long-term neurological conditions compared
with standard care alone, according to the primary outcome of reduction in key symptoms at 12 weeks.
Secondary objectives were to:
l map current practice and document the services available (and common care pathways) for patients
with long-term neurological conditions and their caregivers/families in the areas of the study, to
better understand variations in normal practice experienced by the control group
l test the feasibility of offering short-term integrated palliative care and the trial methods across
five centres for people severely affected by long-term neurological conditions, and to modify the
intervention and trial methods accordingly
l determine the effectiveness of short-term integrated palliative care for people severely affected
by long-term neurological conditions compared with standard care in the secondary outcomes –
palliative care needs and other symptoms, patient psychological well-being and quality of life,
caregiver burden/positivity and quality of life, improvement in patients’ and caregivers’ satisfaction
and communication
l determine the effects of short-term integrated palliative care for people severely affected by
long-term neurological conditions on hospital admissions, length of hospital stay, emergency
attendance and other service use over the trial period
l determine the cost-effectiveness of short-term integrated palliative care for people severely
affected by long-term neurological conditions
l understand how the change process may work and to identify components of the short-term
integrated palliative care that are most valued by patients, their families/caregivers and other
health-care professionals
l determine how the effects change over time, whether or not earlier referral to palliative care
affects the subsequent response to palliative care and when assessment or rereferral might
be beneficial.
Methods
A mixed-methods study comprising a pragmatic, randomised controlled, multicentre, fast-track trial,
assessment of cost-effectiveness, an embedded qualitative component and mapping to understand
standard care.
Mapping and survey methods
Care mapping was conducted in eight centres with neurology and palliative care services in the UK,
purposively selected to include our main recruitment centres and other large centres. Questions
included catchment and population served, service provision and staffing, and integration and
relationships. In addition, neurology and palliative care professionals from six trial centres (London,
Nottingham, Liverpool, Cardiff, Brighton and Ashford) were invited to complete an online survey. The
surveys consisted of multiple-choice or open-comment questions (13 for neurology or 10 for palliative
care). Mapping and survey data were collated, explored and compared.
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Randomised trial methods
People living with multiple sclerosis, idiopathic Parkinson’s disease, motor neurone disease, multiple
system atrophy or progressive supranuclear palsy and their family caregivers were recruited from
seven UK centres. Eligible patients were identified by neurology clinicians as having unresolved
symptoms and/or complex psychosocial needs. Participants were randomised to receive short-term
integrated palliative care immediately (fast-track group) or after a 12-week wait (standard care group).
Short-term integrated palliative care was delivered by multiprofessional teams. The primary outcome
measure was a combined score of eight symptoms as measured by the Integrated Palliative care
Outcome Scale for Neurological conditions (IPOS Neuro-S8) at 12 weeks. Secondary outcomes
included patients’ other physical and psychological symptoms, quality of life, care satisfaction, caregiver
burden, service use and costs, and harms.
Statistical methods
We planned a sample size of 356 patients. This allowed for 17% attrition of the primary outcome at
12 weeks. With two-sided alpha = 0.05 and correlation of 0.40, the study had 80% power for a medium
effect size (0.30). Missingness was explored, with a starting assumption of missing at random. Bivariate
analyses indicated that missingness was associated with patient capacity, age, performance status and
ethnicity. Multiple imputation using chained equations was used to impute missing observations. We
used intention-to-treat analysis. The mean scores and mean change scores from baseline to 12 weeks
post randomisation and their 95% (for primary outcome IPOS Neuro-S8) or 99.55% confidence
intervals (for secondary outcomes) were reported. Statistical significance (0.05/11 = 0.0045) for
secondary outcomes was adjusted using Bonferroni correction to control for multiple testing. The
robustness of the results was explored in six sensitivity analyses.
Health economic methods
Service use data, including inpatient, community, outpatient, home, palliative, rehabilitation and primary
care services, plus tests and diagnostics, were collected using patient report in face-to-face interviews,
according to the Client Service Receipt Inventory. Costs were calculated by combining resource use
data with unit costs obtained from standard sources, in particular the NHS reference cost data in
2015–16 [Department of Health and Social Care (DHSC). NHS Reference Costs 2015 to 2016. 2016.
URL: www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016 (accessed 5 December 2019)]
or the Unit Costs of Health and Social Care 2016 (Curtis L, Burns A. Unit Costs of Health and Social Care 2016.
Canterbury: University of Kent; 2016), when applicable. Cost-effectiveness was assessed by linking
data on health and social care service cost differences and two outcome measurements differences:
the primary outcome IPOS Neuro-S8 and the EuroQol-5 Dimensions, five-level version. Results were
plotted on cost-effectiveness planes. To understand the uncertainty of the results from the incremental
cost-effectiveness ratios, replications of differences in health and social care costs and outcomes were
produced by bootstrapping 1000 times.
Qualitative methods
This explored which aspects of short-term integrated palliative care were most valued or had the
most impact on patients’ and caregivers’ experiences of care, how the change process of short-term
integrated palliative care may be working and how the intervention is delivered in practice. Individual
interviews were conducted with participants who received short-term integrated palliative care.
Interviews were conducted by researchers and research nurses, trained in and supervised during
qualitative interviewing. Focus groups were conducted with health-care staff from the respective
SCIENTIFIC SUMMARY
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centres to explore perceptions of short-term integrated palliative care, processes of short-term integrated
palliative care delivery and the local context of service delivery models for patients with neurological
conditions. Eligible participants comprised health professionals involved in delivering the intervention
in the respective study centres. When individual attendance at a focus group was not possible
(e.g. because of clinical commitments), individual interviews were conducted (either face to face or
by telephone) to ensure representation from all centres. All participants provided written informed
consent. Interviews and focus groups were digitally recorded, transcribed verbatim and anonymised
prior to thematic analysis. NVivo 11 software (QSR International, Warrington, UK) for qualitative
analysis was used for data storage, coding, searching and retrieving, and recording analytical thinking.
Patient and public involvement
An independent patient and public involvement group was set up specifically for OPTCARE Neuro
(OPTimising CARE for people with advanced long-term Neurological conditions), comprising both
patients and caregivers with lived experience of multiple sclerosis, idiopathic Parkinson’s disease,
multiple system atrophy and motor neurone disease. The group advised on the application for ethics
approval and the development of all participant materials, as well as on the delivery of the trial and the
interpretation of the findings. A member of our patient and public involvement group was a co-applicant
on the grant and was on the Study Steering Committee.We had patient and public involvement
representation in the Data Monitoring and Ethics Committee, providing oversight and responsibility for
the conduct of the trial. We actively involved our patient and public involvement members in the
interpretation of data, particularly the qualitative components of this study. This provided valuable
insight to aid understanding of the data and its relevance to addressing patients’ needs.
Ethics approval and research governance
The trial was conducted in compliance with the principles of the Declaration of Helsinki (World Medical
Association. World Medical Association Declaration of Helsinki: ethical principles for medical research
involving human subjects. JAMA 2013;310:2191–4), the principles of Good Clinical Practice and in
accordance with all applicable regulatory requirements. The protocol and related documents were
submitted for review and approved by the London South East Research Ethics Committee (14/LO/1765).
Results
Mapping results
Centres varied in the size of their catchment areas (39–5840 square miles), population served
(142,000–3,500,000) and service provisions. For example, neurology services varied in the number and
type of clinics provided, and palliative care services varied in the settings they covered. The integration
between neurology and palliative care teams varied between centres, and even more so between
diseases. For multiple sclerosis, integration was limited and most centres had no formal links. In
contrast, for motor neurone disease there was established integration and most centres held either
joint clinics or had a palliative care presence at multidisciplinary team meetings. In Parkinson’s disease-
related disorders, integration was mixed, with greater integration reported for multiple system atrophy
and progressive supranuclear palsy.
Survey results
The survey received responses from 33 neurology and 26 palliative care professionals (20% response
rate). Current levels of collaboration between the two specialties were reported as ‘good/excellent’ by
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36% of neurology professionals and by 58% of palliative care professionals. However, nearly half (45%)
of neurology compared with only 12% of palliative care professionals rated current levels as ‘poor/
none’. Both professional groups felt that the new short-term integrated palliative care service being
trialled would improve future collaborations (65–70% in both groups). The most commonly identified
barriers for delivery of the short-term integrated palliative care were resources and clinician awareness.
A key barrier identified by palliative care professionals was the possible need for longer-term care
beyond that offered by the short-term integrated palliative care service.
Randomised trial results
The trial recruited 350 patients (with 229 caregivers), with 176 patients in the immediate short-term
integrated palliative care intervention arm and 174 in the standard care control arm. The groups were
well balanced, except for patient ethnicity, for which there were more patients with ethnicities other
than white in the short-term integrated palliative care group (13%) than in the standard care group
(5%). There were no significant differences in deaths, hospitalisation and survival, up to 12 weeks,
between the trial arms.
Primary analysis of effectiveness
There were no statistically significant differences between the trial arms for either the primary
outcome or any of the secondary outcomes. However, patients receiving short-term integrated
palliative care showed a significant improvement, from baseline to 12 weeks, on the primary outcome
IPOS Neuro-S8 (–0.78, 95% confidence interval –1.29 to –0.26) and the secondary outcome of 24
physical symptoms (–1.95, 99.55% confidence interval –3.60 to –0.30). This was not seen in the control
group, for whom, conversely, care satisfaction significantly lowered from baseline to 12 weeks (–2.89,
99.55% confidence interval –5.19 to –0.59). Subsequent sensitivity analyses reflect these results.
Cost-effectiveness
Health and social care costs (including all inpatient, community, outpatient, home, palliative, rehabilitation
and primary care costs, plus tests and diagnostics) decreased from baseline to 12 weeks (by –£1076 in
the short-term integrated palliative care group and by –£514 in the standard care group). Overall, it
was less costly to provide care for the short-term integrated palliative care group than standard care
(p = 0.12). From an NHS perspective, differences in costs and outcomes resulted in the dominance of
short-term integrated palliative care over standard care: short-term integrated palliative care was less
costly and more effective. The incremental cost-effectiveness ratios for EuroQol-5 Dimensions index
score and rescaled IPOS Neuro-S8 were –£23,545 and –£1519, respectively. Cost-effectiveness planes
for EuroQol-5 Dimensions (quality-adjusted life-year) and IPOS Neuro-S8, showed that, respectively,
> 74% and 84% of replications from bootstrapping were in the fourth quadrant, showing that short-term
integrated palliative care dominated standard care, having both lower costs and better outcomes.
Qualitative findings
Twenty-six interviews were carried out with 26 patients and 16 caregivers from three trial centres
(London, Brighton and Ashford). Two-thirds of patients had multiple sclerosis (18/26). Most had lived
with their condition for a considerable time (mean 13.7 years since diagnosis, standard deviation
10.5 years). Caregivers tended to be younger (caregivers’ mean age was 58.9 years and patients’ mean
age was 63.5 years), 10 out of 16 were women and 11 out of 16 were a spouse or partner. Focus groups
were conducted with 43 health-care staff involved in delivering short-term integrated palliative care
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in six of the study centres. Palliative care team members included consultants in palliative medicine,
clinical nurse specialists, occupational therapists, clinical service managers, a chaplain and an
administrator. Neurology team members included consultants in neurology and disease-specific clinical
nurse specialists.
The value and impact of short-term integrated palliative care, and linkage with key components for
delivery, are encompassed in three overarching themes: (1) adapting to losses and building resilience,
(2) attending to function, deficits and maintaining stability, and (3) enabling caregivers to care. Overall,
the themes illustrate the complexity of living with a long-term neurological condition, the daily work of
patients and caregivers to accommodate ongoing losses and adapt to maintain stability in function, and
achieve optimal management of disease and symptoms. The strategies used were typically honed over
many years. There were rarely ‘quick fixes’. What was required was skilled support with attention to
the multiple domains of health and person-centred care, to understand priorities and integrated
working across health care, and to optimise continuity of care and treatment.
Conclusions
To the best of our knowledge, this is the largest palliative care trial in people with a variety of
long-term neurological conditions. Although no significant between-group differences were seen, we
found that short-term integrated palliative care provides improvements in patient-reported physical
symptoms, at a lower cost and without any harmful effects when compared with standard care.
However, further work is needed to refine short-term integrated palliative care and the provision of
holistic, palliative care approaches for this patient group, with a particular focus on better integration
of existing services, research into ways to alleviate some of the more intractable symptoms, as well as
the appropriate timing and criteria for referral of long-term neurological condition patients to specialist
palliative care.
Trial registration
This trial is registered as ISRCTN18337380.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Services and
Delivery Research programme and will be published in full in Health Services and Delivery Research;
Vol. 8, No. 36. See the NIHR Journals Library website for further project information.
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Long-term neurological conditions (LTNCs) are a diverse set of conditions resulting from injury or
disease of the nervous system that affect individuals for the rest of their lives. This includes long-term
progressive conditions, such as idiopathic Parkinson’s disease (IPD), motor neurone disease (MND),
multiple sclerosis (MS), progressive supranuclear palsy (PSP) and multiple system atrophy (MSA).
Affecting > 200,000 individuals in the UK, these progressive conditions lead to substantial deterioration
in quality of life and result in the patient needing lifelong support from health and social care services.1
Many patients have inadequate symptom control and inadequate psychological and social support, and
there is a high burden for family caregivers.2–5 There are also significant financial burdens to the individual,
their families and the NHS, with increasing costs associated with disease progression.6–8 Despite the
progressive nature of these conditions, the scope for improving services to enhance quality of life of
affected individuals through the provision of palliative care may be substantial.
Current treatment and service provision
In 2005, the Department of Health and Social Care published the National Service Framework, which
set 11 quality requirements to transform the way health and social care services support people with
LTNCs and their caregivers.9 It highlighted the need for integrated care and joined-up services, and
made recommendations for the provision of specialist neurology, rehabilitation and palliative care
services to support people throughout and to the end of their lives.
However, a National Audit Office report concluded that implementation of the framework has been
poor and that although access to neurology services improved, other important indicators of the
quality of care for people with neurological conditions worsened.10 The report highlighted that
information and advice to patients and caregivers is inadequate, and ongoing care is fragmented and
poorly co-ordinated. Indeed, in the UK and in many other health systems, there is often division
among general practitioners, staff working in the community and hospital-based specialists.11,12 It is
increasingly recognised that a hard separation of these functions does not meet the needs of those
with long-term conditions; therefore, much of the burden of illness often falls on the community and
on lay caregivers.2,5,13,14 This results in greater negative effects for both patient and caregiver well-
being, as well as increased financial burden.8,15 Attempts have been made to better co-ordinate care
through integrative processes, such as joint budgets, governance, information systems, flows of data or
case management.16,17 These may be brought together more formally through different kinds of vertical
integration, in which agencies involved at different stages of the care pathway form part of a single
organisation or function, as well as horizontal integration of community-based services in examples
such as health and social care teams for the frail elderly.18 Another issue is that multimorbidity is the
norm for people with LTNCs. Equally, their spouses or family caregivers may have health conditions
that affect their ability to care, and the burden of caring may affect the health of caregivers.2,13
Palliative care is person rather than disease focused and may have the potential to address these
unmet needs.
Palliative care for long-term neurological conditions
Palliative care focuses on improving quality of life through a multidisciplinary approach and has
been recognised as a valuable component of care for patients with chronic, life-limiting illnesses.19–21
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The place for palliative care in rapidly fatal neurological conditions is increasingly recognised; however,
the evidence is scarce.22 Indeed, a recent consensus review concluded that there is limited evidence to
support any recommendations for the provision of palliative care for progressive neurological disease
and that further research is urgently needed.23 There are three Phase II trials of palliative care for
patients with neurological conditions.24–26 The results of our own Phase II trial of short-term integrated
palliative care (SIPC) among 52 patients severely affected by MS found an improvement in pain and a
significant reduction in informal caregiver burden at a lower cost and with no harmful effect, compared
with standard care.24 Similarly, in 78 MS patients and their caregivers, a 6-month home-based palliative
care service was found to reduce symptom burden compared with usual care.26 Furthermore, a new
4-month home-based specialist palliative care service for 50 patients with advanced neurodegenerative
disorders (MND, MS, IPD, MSA and PSP) found a significant improvement in quality of life and physical
symptoms (pain, breathlessness, sleep disturbance and bowel symptoms) across the conditions,
although no effect was seen on caregiver burden.25 We have also previously reported findings from
a longitudinal observational study of IPD, MSA and PSP patients demonstrating the profound and
complex mix of non-motor and motor symptoms in late stages of disease.27 Symptoms were highly
prevalent in all three conditions and were often unresolved, with half of patients deteriorating over
1 year. Furthermore, palliative problems were predictive of future symptoms, suggesting that an early
palliative assessment might help screen for those in need of earlier intervention.27 However, to the
best of our knowledge, there are currently no Phase III trials.
Conceptual framework
People severely affected by LTNCs have many problems and concerns similar to those affected
by advanced cancer, including symptoms, psychological needs, and family and caregiver concern.28
Specialist multiprofessional palliative care teams (MPCTs) successfully improve these problems
for cancer patients and are now available widely across the globe.29,30 The Cochrane handbook
outlines31 that, if there is empirical evidence that similar or identical interventions have an impact
on other populations, these are quite likely to be effective. Thus, as a starting point, it is reasonable to
hypothesise that input from specialist palliative care will help people with LTNCs. Our modelling work
demonstrated that people severely affected by MS, Parkinson’s disease-related disorders and MND
had many similar symptoms to those affected by advanced cancer,32 with additional problems of loss
of care co-ordination.33–35 These needs are within the remit of specialist palliative care, which offers
a holistic approach attending to symptoms, psychological needs and better co-ordination of care.36
People severely affected by LTNCs often have a longer trajectory of illness than those with advanced
cancer and so our modelling found that staff, patient and caregiver groups favoured the idea of
specialist palliative care input for a short term, working in a way that was well integrated with existing
neurology and rehabilitation services.
Short-term integrated palliative care is modelled on our work to date, following the Medical Research
Council guidance for the development and evaluation of complex interventions.37 This included
literature reviews38 and qualitative studies33,34 to determine need and to develop the theoretical
underpinning of the service, appraisal of trial methods,32,39 service modelling and a successful Phase II
trial randomising 52 patients.24,29,40
Short-term integrated palliative care is a complex intervention41 in that it:
l contains several components (assessment, symptom management, future care planning, follow-up
visits)
l aims to change behaviours by those staff delivering the intervention, those providing usual care to
this patient group, and, to some extent, patients and families
l targets patients, families and staff in primary, hospital and voluntary care, thus including different
groups and organisational levels
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l has several complex outcomes, including change in symptom management and hospital admissions
l is tailored to individual patient need and circumstances by those delivering SIPC
l operates in a context in which there may be some variability between patient groups and settings in
the usual care provided to patients with LTNCs; usual care is offered to patients in the intervention
and control arms of the trial.
Short-term integrated palliative care could be developed with only small adaptions to existing health-
care services. It is much more likely to be possible than other proposed alternatives, such as developing
long-term palliative care models. The latter would be difficult to achieve without considerably expanding
the number of palliative care specialists, beds and services. In contrast, SIPC builds on and integrates
with existing services across the UK and seeks to empower patients, improve symptom control and
integrate with existing services, improving their expertise. If found to be effective, the new SIPC service
has the potential to be beneficial for a wider range of conditions and in more diverse care settings for
patients and their families. This could result in better symptom control and improved quality of life for
patients, as well as improved co-ordination of care, more efficient and appropriate use of services, and
a reduction in the number of unnecessary emergency admissions at the end of life. This is also in line
with other NHS initiatives seeking to move palliative care and discussions about preferences and
priorities further upstream and encouraging patients to think about care preferences earlier in their
disease trajectory.42 Understanding whether or not SIPC is clinically effective and cost-effective, and
its potential mechanism of action, will help to develop studies in these initiatives. Equally, if the SIPC
is not cost-effective in more conditions and in wider settings, the findings will prompt development of
customised improvement and modifications in specific LTNCs.8,43–45
Importance of economic analysis
Health-care costs in the last year of life are high (18–30% of health-care spending), with resource use
increasing in the last months of life.43–45 Despite this, it is known that this expenditure offers poor value,
as symptoms often remain uncontrolled.46 In long-term conditions, including neurological conditions,
costs rise with increased disability and as the disease advances.8 These costs can be unpredictable and
can affect caregivers and patients, as well as health and social services.8 Hospitalisation is a main cost
driver of health care and a major public health problem. Indeed, NHS England reports that £750M is
spent on urgent and emergency care for patients with neurological conditions, including admissions to
hospital, with nearly 4% growth in emergency admissions year on year.47 Compared with age-matched
controls, people with LTNCs, such as MS and Parkinson’s disease, are experiencing higher rates of
hospitalisation.48–50
However, maintaining patients in the community can also be costly to health and social care services.
It can also place an increased burden on families and carers. Therefore, it is imperative to evaluate
proposed service models in patients with advanced disease to see whether or not they affect health
and social care costs. SIPC seeks to alleviate symptoms, prevent symptom escalation, improve care,
and help patients and caregivers plan the future care they need, all of which may potentially avoid
inappropriate hospitalisation. A full understanding of the cost-effectiveness of SIPC for the NHS is
central to decision-making. Despite this need, health economic evaluations of interventions in
advanced illness remain rare, especially cost-effectiveness studies. Most studies consider only costs,
randomised trials are rare and many studies fail to account for confounding.51,52
Evaluating a new service model for LTNCs, as well as addressing the concerns for people severely
affected by these diseases, develops a potential model of service provision for other long-term diseases
in advanced stages. With the ageing population, the predicted rise in the annual number of deaths, the
increasing prevalence of long-term conditions and the likely increase in need for palliative care,53,54 it is
both highly relevant and timely to robustly test new service models to improve care for this group.
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This project answers this need and tests an intervention that could be implemented by the current
workforce and services.
Research group
This project was led by the Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation at
King’s College London, with the following collaborating institutions: The University of Nottingham;
Nottingham University Hospitals NHS Trust; Cardiff and Vale University Health Board; University of
Sussex; Brighton and Sussex Medical School; The Walton Centre NHS Foundation Trust; Sussex
Community NHS Foundation Trust; Ashford and St. Peter’s Hospitals NHS Foundation Trust; Sheffield
Teaching Hospitals NHS Foundation Trust and King’s College Hospital NHS Foundation Trust.
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Chapter 2 Aim and objectives
Aim
The OPTCARE Neuro trial aimed to determine the clinical effectiveness and cost-effectiveness of SIPC
services in improving symptoms, improving selected patient- and caregiver-reported outcomes and
reducing hospital utilisation for people severely affected by LTNCs.
Primary objective
To determine the clinical effectiveness and cost-effectiveness of SIPC for people severely affected by
LTNCs compared with standard care, according to the primary outcome of reduction in key symptoms
at 12 weeks.
Secondary objectives
l To map current practice and document the services available (and common care pathways) for
patients with LTNCs and their caregivers and families in the areas of the study, to better understand
variations in normal practice experienced by the control group.
l To test the feasibility of offering SIPC and the trial methods across five centres, for people severely
affected by LTNCs, and to modify the intervention and trial methods accordingly.
l To determine the clinical effectiveness and cost-effectiveness of SIPC for people severely affected
by LTNCs compared with standard care in the secondary outcomes: palliative care needs and other
symptoms, patient psychological well-being and quality of life, caregiver burden/positivity and
quality of life, improvement in patients’ and caregivers’ satisfaction and communication.
l To determine the effects of SIPC for people severely affected by LTNCs on hospital admissions,
length of hospital stay, emergency attendance and other service use over the trial period.
l To determine the cost-effectiveness of SIPC for people severely affected by LTNCs.
l To understand how the change process may work and to identify components of the SIPC that are
most valued by patients, their families and caregivers, and other health-care professionals.
l To determine how the effects change over time, whether or not earlier referral to palliative care
affects the subsequent response to palliative care and when assessment or re-referral might
be beneficial.
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Chapter 3 Design and methods
Study design
This is a mixed-methods study comprising a Phase III, randomised controlled, multicentre, fast-track
trial, including assessment of cost-effectiveness and an embedded qualitative component. It is a
multicentre evaluation of a complex intervention, following the Medical Research Council guidance for
the development and evaluation of complex interventions.37 This study incorporates:
1. a set-up and feasibility phase to refine recruitment and methods
2. mapping usual care for patients with LTNCs across the different centres (by prior work collecting
information about the services, and during the study recording services received at baseline and
in the standard care group) to understand the context and baseline variations in practice
and resources
3. a randomised controlled trial of SIPC offered from a MPCT, compared with best usual care in terms
of outcomes and cost-effectiveness
4. an embedded qualitative component, to explore the ways in which the SIPC affects patients and
caregivers, how the change process may work, how SIPC may be improved and to interpret
quantitative results
5. a survey of health professionals to understand the impact of SIPC on local practice
6. economic modelling to estimate the NHS and societal resources required for and longer-term
impacts of SIPC.
Mapping methods
Parts of the text have been reproduced from van Vliet et al.55 This article is distributed under the
terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made
available in this article, unless otherwise stated.
The mapping exercise was conducted in eight centres with neurology and palliative care services in the
UK. The centres were purposively selected to include our main recruitment centres and other larger
centres. The eight centres included different geographical areas and represented both rural and urban
areas. Data were provided by the respective neurology and specialist palliative care teams. Questions
focused on catchment and population served, service provision and staffing, and integration and
relationships. Data were transferred into tables to facilitate comparison between centres.
Survey methods
Parts of the text have been reproduced from Hepgul et al.56 This is an Open Access article distributed
in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original
work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
DOI: 10.3310/hsdr08360 Health Services and Delivery Research 2020 Vol. 8 No. 36
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Hepgul et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
7
Research teams from six trial centres (London, Nottingham, Liverpool, Cardiff, Brighton and Ashford)
identified local neurology and palliative care professionals who were then approached via e-mail by the
central trial team. Professionals were informed that, by completing the survey, they provided informed
consent for use of their anonymised data. The surveys consisted of multiple-choice or open-comment
questions, 13 questions for neurology or 10 questions for palliative care, with responses collected
using online forms. The survey was launched in July 2015 and closed in April 2016. Data were
transferred into tables to facilitate comparison of professional groups and data were explored
descriptively.
Randomised trial methods
This was a randomised controlled, multicentre, fast-track, single-blinded trial of SIPC, provided in addition
to existing services, compared with standard care. It was conducted and reported in accordance with
Consolidated Standards of Reporting Trials (CONSORT)57 and Methods of Researching End of Life Care
(MORECare) statements.58 The economic components were conducted and reported in accordance with
the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.59
Settings
The trial recruited patients and caregivers from seven centres in the UK (South London, Nottingham,
Liverpool, Cardiff, Brighton, Ashford and Sheffield), all with MPCTs and neurology services. In all the
centres, neurology services are consultant led with clinical nurse specialists for the relevant conditions.
The majority of patient contacts are hospital based, with variable community outreach work. The
centres’ respective local areas have networks of palliative care services, including inpatient hospices,
community services and hospital support teams. The centres encompass urban, suburban and rural
areas, with varying levels of deprivation and ethnic diversity.
Inclusion criteria
Eligible patients were:
l adults (aged ≥ 18 years) severely affected by advanced or progressive stages of either:
¢ MS – patients with either aggressive relapsing disease with rapid development of fixed disability
or with advanced primary or secondary progressive disease, often with limitations, such as gait
and upper limb function (we did not define referral based on disability, but expected most
patients to have an Expanded Disability Status Scale60 of at least 7.5)
¢ Parkinsonism and related disorders:
¢ IPD Hoehn and Yahr scale61 stages 4–5
¢ PSP Hoehn and Yahr scale61 stages 3–5
¢ MSA Hoehn and Yahr scale61 stages 3–5
¢ MND all stages
l deemed (by referring/usual care clinicians) to have:
¢ an unresolved symptom (e.g. pain, breathlessness) that has not responded to usual care
¢ at least one of the following: another unresolved other symptom; cognitive problems; complex
psychological (depression, anxiety, family concerns) needs; complex social needs; communication/
information needs
DESIGN AND METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
8
l able to give informed consent, or their capacity can be enhanced (e.g. with information) so that they
can give informed consent, or a personal consultee can be identified and approached to give an
opinion on whether or not the patient would have wished to participate
l living in the catchment area of the SIPC service.
Eligible caregivers were:
l adults (aged ≥ 18 years) identified by the patient as the person closest to them, usually a family
member, close friend, informal caregiver or neighbour
l able to give informed consent and to complete the questionnaires.
Eligible professionals were:
l professionals involved in the care of patients with LTNCs
l professionals (of neurology or palliative care services) who are part of a team involved in the
delivery of the OPTCARE Neuro intervention.
Exclusion criteria
Patients who met the inclusion criteria, but:
l were already receiving specialist palliative care or had done so in the last 6 months
l lacked capacity and had no family member, friend or informal caregiver willing and available to
complete questionnaires about their own and the patient’s symptoms and circumstances.
Recruitment procedure
Potential participants were identified through neurology teams (consultants and clinical nurse
specialists) at outpatient clinics. Research nurses liaised directly with these teams, attending clinics
when possible to ensure the accuracy of eligibility assessment. Awareness of the trial was raised by:
l conducting local workshop sessions (e.g. lunchtime seminars) at recruiting centres to explain why
the trial is being conducted; equipoise; how to identify and refer patients; and general information
on palliative care needs
l developing posters and flyers detailing the trial, the local research personnel and lead clinicians,
to be displayed in appropriate places
l working with our patient and public involvement (PPI) group, as well as other patient societies
and charities.
Identifying clinicians discussed the trial with potential participants and provided written information
when possible. If patients were interested and agreed to it, clinicians completed a standard referral
form to check that the inclusion criteria were met and this was then sent to the local research teams.
The research teams contacted patients by telephone to explain the trial, sent out written information
if not already received and subsequently arranged a first visit (after a minimum of 24 hours unless the
potential participant wished to waive this period). We also aimed to gather the views of informal
caregivers and, when appropriate, asked patients to identify the person nearest to them (such as a
family member or informal caregiver) who could also be approached to participate in the trial. If the
caregiver was interested and met the inclusion criteria, they were also presented with written
information regarding the trial. At the initial visit, researchers provided potential participants (patients
and caregivers) the opportunity to further discuss the trial and ask any questions. Following this,
written informed consent was obtained and baseline questionnaires administered with patients and
their caregivers. As part of the consenting process, researchers discussed the need for the patients to
nominate a consultee in case their capacity fluctuated during the course of the trial (see Mental
Capacity Act).
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If a patient met the inclusion criteria but the clinical team or researcher deemed them (using clinical
judgement, in line with local policy guidance) to have reduced capacity, inclusion was discussed with
informal caregivers, family members or close friends (in conjunction with the patient if appropriate) to
determine the most appropriate person to act as the personal consultee. The research teams contacted
the nominated personal consultee to explain the study, provide written information and subsequently
arrange a first visit (after a minimum of 24 hours, unless the personal consultee wished to waive this
period). At this initial visit, the patient was reassessed and if capacity was confirmed to be insufficient,
the consultee was asked to confirm whether or not they believed the patient would like to be included
in the trial and provided assent on their behalf. When caregivers provided assent for a patient lacking
capacity, they were also asked to provide proxy information about the patient.
Mental Capacity Act
The commonality of cognitive impairment in advanced LTNCs required the inclusion of people with
impaired mental capacity in the trial. The Mental Capacity Act62 informed the process of consent
for patients lacking capacity. All participants were considered to have capacity unless established
otherwise and all practicable steps were taken to enable individuals to decide for themselves if they
wished to participate. Capacity was established using the Mental Capacity Act four-step process:
1. The individual is able to understand the information about the study.
2. The individual is able to retain the information (even for a short time).
3. The individual is able to use or weigh up that information.
4. The individual is able to communicate their decision.62
A process of consent and assent tailored to an individual’s level of capacity and incorporating varying
levels of capacity was used. Incorporating different processes of consent and assent has been
successfully used in previous studies on end-of-life care.63–65 For adults lacking capacity, a personal
consultee was sought to give an opinion on whether or not the patient would have wanted to
participate in the study had they had capacity to indicate this, and whether or not that participation
would cause undue distress.62,65 For adults with impaired capacity who were able to understand, retain
and weigh-up information in the moment, a process of consent in the moment was used, with ongoing
consent whereby informed consent to participate was reaffirmed prior to each data collection point.66
If a participant’s capacity declined so that they were no longer able to give informed consent in the
moment, researchers followed the procedure for adults lacking capacity as detailed above.
Advance consent was incorporated in the consent process for all patients in anticipation that some
may lose capacity over the course of the trial and no longer have capacity to indicate their right to
withdraw. The process of advance consent was informed by previous studies with older people65 and
on end-of-life care.67 Participants were asked to indicate if, should they lose capacity in the future,
they wished to continue to be involved in the trial and, if yes, asked to nominate a personal consultee.
The personal consultee was approached if the participant lost capacity to such an extent that they
were no longer able to indicate their right to withdraw or to complete patient-reported outcome
measures, requiring instead a proxy informant (e.g. informal or formal caregiver). The procedure of
assent for adults lacking capacity was followed to ascertain the personal consultee’s opinion on the
individual’s continued participation.
Data collection
Face-to-face visits were undertaken with patients at their location of choice (usually their home).
Trained research nurses and researchers assisted, as required, in self-completion of patient and
caregiver questionnaires, in accordance with the standardised schedule. Data were collected at
baseline and then at 6, 12, 18 and 24 weeks post randomisation. Usually, caregivers self-completed
their questionnaires during the patient interview but in some instances questionnaires were returned
by post to the local project teams. For adults lacking capacity, baseline and outcome measures were
obtained from the informal caregiver interviewer, as above. The use of a proxy informant is common in
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research on palliative care associated with patients’ advancing illness and deteriorating condition, and
on the importance of capturing data at points of deterioration when a patient may most benefit from
palliative care, notably the last days of life. In addition, informal caregivers provided the baseline
information about the patient’s demographic circumstances and clinical history (e.g. age, educational
level, diagnosis, time since diagnosis), as would normally be collected in the patient interview. Outcome
assessors were blind to treatment allocation and accommodated separately from the intervention teams.
Outcome measures
The primary outcome was the combined score of eight key symptoms (pain, shortness of breath,
nausea, vomiting, constipation, spasms, difficulty sleeping and mouth problems), as measured by the
Integrated Palliative care Outcome Scale for Neurological conditions 8 symptom subscale (IPOS
Neuro-S8) at 12 weeks. The IPOS Neuro-S8 has been validated among people with LTNCs and found
to be responsive to change.68 The choice of primary outcome was based on the results of our Phase II
trial and our modelling work: patients consider these important symptoms in neurological conditions;
the SIPC aims to improve several complex symptoms that interact; and these symptoms are often
overlooked by existing services but impact on quality of life. Secondary outcomes (all also measured at
baseline and 12 weeks) included the following.
Patient outcomes
l Patients’ palliative needs and symptoms, as measured by the IPOS Neuro, composed of 42 items,
for which higher scores indicate more palliative care needs.
l Patients’ physical symptoms as measured by the Integrated Palliative care Outcome Scale for
Neurological conditions 24 symptom subscale (IPOS Neuro-S24) subscale,69 composed of 24 items,
for which higher scores indicate more symptom burden.
l Patients’ psychological and spiritual well-being, information needs and practical issues, as measured
by the IPOS Neuro-8 non-physical subscale, composed of eights items, for which higher scores
indicate more palliative care needs.
l Patients’ psychological distress, as measured by the Hospital Anxiety and Depression Scale
(HADS),70 composed of two separate subscales for anxiety and depression, each with seven items,
for which higher scores indicate more distress.
l Patients’ satisfaction of care, as measured by the modified FAMCARE-P16,71 composed of 16 items,
for which higher scores indicate more satisfaction with care.
l Patients’ self-efficacy, as measured by the Self-Efficacy for Managing Chronic Disease (SEMCD) Scale,72
composed of six items, for which higher scores indicate more self-efficacy.
l Safety, adverse events and survival (days from consent to death).
Health economic outcomes and service use
l Patients’ health-related quality of life and well-being as measured by the EuroQol-5 Dimensions,
five-level version (EQ-5D-5L),73 composed of five dimensions plus a visual analogue scale, for which
higher scores indicate better quality of life.
l Hospital admissions, emergency attendances and other health and social care service use, including
inpatient, outpatient, home-based services, and tests and diagnostics, as measured by the adapted
version of the Client Service Receipt Inventory (CSRI).74
Caregiver outcomes
l Caregiver burden as measured by the Zarit Burden Inventory 12 items (ZBI-12),75 composed of
12 items, for which higher scores indicate more burden.
l Caregiver positivity as measured by the ZBI-12 and positivity,75 composed of eight items, for which
higher scores indicate more positivity related to caregiving.
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l Caregiver satisfaction as measured by the modified FAMCARE 2,71,76 composed of 17 items,
for which higher scores indicate more carer satisfaction with patient care.
l Caregiver assessment of patients’ problems and services, as measured by the IPOS Neuro and
the CSRI.
Intervention
The SIPC focused on personalised care planning, case management and supporting existing care
providers.17 The SIPC was delivered by existing MPCTs, linked with local neurology and rehabilitation
services. MPCTs comprised individuals specifically trained in palliative care from backgrounds in
medicine, nursing or social work, together with other allied health professionals. All staff involved in
the delivery of the intervention were provided with a standard manual and face-to-face training in
advance of the trial commencing. For the purposes of the trial, MPCTs operated a key worker process,
in which a specialist team member took initial responsibility for a referred patient.
Frequency and duration of intervention
The length of the intervention was 6–8 weeks from referral. This is broken downs as follows:
l 2 days for first telephone call (from receiving the patient referral).
l Up to 5 days for first visit (i.e. end of week 1).
l 2–3 weeks for second visit (i.e. end of week 3–4).
l 3–4 weeks for third visit (i.e. end of week 6–8).
Following referral, a key worker (usually a specialist palliative care nurse) contacted the patient within
2 working days to arrange a visit within the next 5 working days to undertake a comprehensive
palliative care assessment. As would be standard palliative care practice, at this initial visit a
comprehensive palliative care assessment was undertaken, considering both patient and caregiver/
family needs. The SIPC manual and training specified the following components to be covered in this
assessment:
l history to include illness understanding
l completion of IPOS Neuro to aid identification of patient symptoms and needs
l symptom control and management
l continuity and co-ordination of care, access to services
l psychosocial needs
l information/communication needs
l practical needs at home
l decision-making and advance care planning
l assessment of caregiver and family needs
l medication review
l referrals/appointments with other care providers
l provide information about what is provided through SIPC, along with contact details.
Following this initial assessment, a problem list was generated and prioritised, and a proposed
treatment plan agreed with the patient and their family. This may have involved a change in symptom
management (e.g. medicine change), contact with other services and/or psychosocial support or
counselling. Medicine change recommendations were in liaison with the patient’s general practitioner
and/or neurologist, as appropriate, and followed regional and national best practice guidance (e.g. the
Palliative Care Formulary77). The treatment plan for each patient was discussed and reviewed at a
multiprofessional team meeting, to optimise the management of the patient and caregiver. A summary
and action plan were then sent to the patient and all relevant health professionals.
The second contact (face to face or telephone) normally occurred within 2 weeks of the first visit, in
order to review and evaluate the proposed plan of care. When appropriate, this included liaison with
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relevant health professionals for exchange of information, advice and co-ordination of care. The
personalised problem list and plan were reviewed and updated, with a copy sent to the patient and all
relevant health professionals. The final contact involved a review of outcomes from actions already
taken and then discharge to local services, as appropriate. Specialist palliative care is always an
individualised service responding to patients’ needs, and SIPC was intended to be the same; therefore,
there was some flexibility to adjust to patients’ and families’ individual needs and requirements, and
some patients needed prompt support after the first or second visit.
Patients and caregivers in both arms continued to receive usual care throughout the duration of the
trial, regardless of trial arm allocation. This included support from specialist nurses, neurology services
(outpatient and inpatient), rehabilitation services, community services, general practitioners, district
nurses and social services.
Standardisation and compliance
To understand the delivery of the intervention, all MPCTs completed standardised documentation for
each patient, recording the main activities and services provided. Each team was advised to use their
own existing paper-based or electronic clinical records, in order not to duplicate work for busy clinical
teams; however, they were asked to review their usual documentation to ensure that, as a minimum,
they record and report:
l mode of contact and duration for each contact
l clinical details and severity of main problems
l activities performed during contact, plan of care and referrals to other services
l phase of illness (stable, unstable, etc.)
l performance status using the Australia-modified Karnofsky Performance Scale (AKPS)
l level of compliance was using the following classifications: complier (received full intervention
as planned), partial complier/erratic user (received some but not all of the intervention, or
recommendations not followed), overuser (in frequent contact with the service) and dropout.
Randomisation, blinding and allocation concealment
Following consent and baseline data collection, local research nurses entered the patients’ data and
registered each patient on the online database [InferMed MACRO-4 (London, UK)]. The registration
process allocated each patient a unique participant identification number, which was used to identify
them throughout the course of the trial. Once the patient was registered and the baseline data were
verified, the trial manager performed all randomisations centrally using an online randomisation system
managed by the King’s College London Clinical Trials Unit (CTU).
Randomisation was performed in a 1 : 1 ratio, at the patient level, with minimisation for centre, primary
diagnosis (MS vs. IPD vs. PSP, MSA and MND) and cognitive impairment (capacity vs. impaired or
lacking capacity). The trial manager was notified of the trial arm allocation and arranged referrals to
the palliative care teams for the intervention accordingly (i.e. immediately or after completion of the
12-week data collection visit). As the randomisation used a dynamic method via a system managed by
the CTU, it was not possible for the investigators or the trial manager to know the allocation sequence
in advance.
The research nurses conducting the data collection interviews and the trial statistician were blinded to
the allocation, but received blinded randomisation confirmation e-mails. The trial manager telephoned
patients and/or caregivers to inform them of their trial arm allocation and when they would be
contacted by the palliative care team. During this telephone call, they were asked not to reveal their
allocation to the research nurses at subsequent visits. This information was also sent to all participants
in writing, worded as ‘It is important that you do not tell the researchers which group you have been
assigned to. This is important for the information we collect from you’. After the primary end point of
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12 weeks, in a small number of cases, research nurses were unblinded in order to conduct the
qualitative interviews with patients and caregivers who had received the intervention.
Statistical methods
Sample size
Based on the data from our Phase II MS trial,40 the total required sample size required for five centres
was 356 patients. In view of the advanced illness in this patient group, this included allowing for
17% attrition to the primary outcome at 12 weeks, giving 296 patients, or 148 in each arm, with data
at both baseline and 12 weeks. The correlation between baseline and the outcome at 12 weeks in the
pilot study was 0.55. Using a generalised linear model to adjust for the baseline score, with two-sided
alpha = 0.05 and correlation of 0.40, the study will have 80% power for a medium effect size of 0.30.
To allow for heterogeneity across conditions and centres, we used conservative figures (e.g. correlation
0.4 rather than 0.55; 17% attrition) to estimate the sample size.
Descriptive analysis
Continuous variables were summarised with descriptive statistics [n, mean, standard deviation (SD),
median, minimum and maximum]. Frequency counts and percentage of subjects within each category
were provided for categorical data. No significance testing was carried out. Summary tables
(descriptive statistics and/or frequency tables) by trial arm were provided for all baseline variables,
including demographic and clinical characteristics, cognitive impairment and functional performance
status. Summary tables were also provided by those with and without valid primary outcome data
(IPOS Neuro-S8 score at 12 weeks) (see Appendix 2).
Missing data
Attrition was summarised in accordance with the MORECare classification as attrition due to death,
attrition due to illness or attrition at random.58 For baseline and outcome data, the number with
complete data at both time points is reported. The mechanism of missingness was assumed as missing
at random, as bivariate analyses indicated that missingness was associated with patient capacity, age,
performance status and ethnicity. Multiple imputation using chained equations was used to impute
missing observations. Imputation models included the outcome variable of interest, a binary measure
of patient capacity, patient age, patient performance status (as measured by the categorical AKPS
measure) and a binary measure of patient ethnicity (white vs. other ethnicities). Twenty imputed values
were generated for each variable with missing data, which were then combined as per Rubin’s rule.78
Effectiveness analysis
Data were analysed on an intention-to-treat basis. The mean scores, mean change scores from baseline
to 12 weeks post randomisation and their 95% (for primary outcome – IPOS Neuro-S8) or 99.55%
confidence intervals (CIs) (for secondary outcomes) were reported. To account for clustering effects,
a generalised linear mixed model (GLMM), with centre as a random effect, adjusting for baseline score
of IPOS Neuro-S8 was used. For each of the primary and secondary outcomes, the change score was
regressed on to the binary measure of trial arm. The statistical significance value (0.05/11 = 0.0045) for
secondary outcomes was adjusted using Bonferroni correction to control for multiple testing.
Sensitivity analysis of effectiveness
Six sensitivity analyses followed for the primary and secondary outcomes. In the first, the analyses
were adjusted for ethnicity (as between-arm differences were observed in additional exploratory
analysis), using fully imputed data (n = 350). In the second, the two participants who were deemed
ineligible for the study post randomisation were excluded; thus, the complete data set totalled
348 patients. The third and fourth sensitivity analyses assessed differences in change scores between
trial arms in complete patient and caregiver data, respectively. The fifth sensitivity analysis used complete
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patient data, if available at both baseline and 12 weeks, and imputed proxy carer data if not. Caregiver
data were used only when complete and available, at both baseline and 12 weeks, ensuring that scores
were acquired from the same source (patient or caregiver) at both time points. The sixth sensitivity
analysis included only patients with MS. For each of the sensitivity analyses, differences between change
scores for each trial arm were tested using GLMM, adjusting for baseline scores.
Health economic methods
An economic component was included to assess the cost-effectiveness of SIPC compared with
standard care. Cost-effectiveness was assessed by linking data on formal cost differences and outcome
measurements differences.
Service use
Participants provided details of services used during the 12 weeks prior to baseline and then for the
past 12 weeks post randomisation, using a version of the CSRI.74 Services included hospital inpatient
and outpatient care, primary health care (home care and community care), tests and diagnostics, social
care, the provision of aids and home adaptations, and informal care provided by family members
and/or friends. The number of contacts with services and, when relevant, the mean length of contacts
were documented. The number of hours that family and friends spent providing personal care and help
inside and outside the home and in other tasks per week was collected. To better understand the utilisation
and associated costs, service items were grouped into health and social care (outpatient, day or community,
home, palliative, rehabilitation, primary, social care, and tests and diagnostics) and informal care.
Missing data
For those participants who completed the CSRI, a blank return in the questionnaire on whether or not a
participant used a specific service was assumed to indicate no use of that particular service. This followed
the structure of CSRI questions. CSRI asks respondents to describe what services or care they have
received, to tick when services are received, and then say how often and how much of these they
received. It offers a long list of potential options and an open space to describe others. It does not ask
‘yes or no’ for each service in the long list, and the space can be left blank when services are not used.
When a service was used, but either the number of contacts or duration of contacts was unknown,
the median value from all other valid cases across the whole sample at that time point was used.
Missing data for the outcome variables [IPOS Neuro-S8 and EuroQol-5 Dimensions (EQ-5D) index
score] were imputed using multiple imputation with chained equations after examining the associations
between missingness and variables of interest such as patient capacity, age, performance status and
ethnicity. For those participants who provided outcome data but no CSRI data, total care (health and
social care and informal care) costs were also imputed, as described above.
Costs
Costs were calculated, in Great British pounds, by combining resource use data with unit costs obtained
from standard sources, such as the NHS Reference Costs 2015 to 201679 or the Unit Costs of Health and
Social Care 2016,80 where applicable. The unit costs of a home care worker or a nurse aid were used as a
proxy for informal care. We assumed that the CSRI recorded all services provided for the participants,
regardless of randomisation, and did not separate the services of the intervention from the rest.
The horizon of the analysis is restricted to the trial period and no discounting was considered.
Cost-effectiveness analysis
Cost-effectiveness, from an NHS perspective, was assessed by linking data on health and social care
service cost differences and two outcome measurements differences: the primary outcome IPOS
Neuro-S8 and EQ-5D index score [quality-adjusted life-year (QALY)]. IPOS Neuro-S8 total score was
generated as the sum of eight items, ranging from 0 to 32. For cost-effectiveness analysis, this was
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rescaled by subtracting from 32 to make higher scores reflect better outcomes. EQ-5D-5L contains
five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each of
which has five levels (no problems, slight problems, moderate problems, severe problems and extreme
problems). These levels are valued 1–5, respectively; however, as these numerals have no arithmetic
properties and should not be used as a cardinal score, we calculated an index value using UK value sets
for EQ-5D obtained by a crosswalk approach.81
The mean and SD were examined for formal care costs and the two outcome measurements. Cost-
effectiveness of SIPC was assessed by calculating incremental cost-effectiveness ratios (ICERs), using
mean changes in formal care costs and outcome measurements, as shown in Equation 1. ICERs smaller
than the willingness-to-pay (WTP) threshold (λ = e.g. £20,000, as the threshold used by the National
Institute for Health and Care Excellence) indicates that the cost-effectiveness of SIPC. The primary
decision criterion for cost-effectiveness of SIPC was whether ICERs were larger or smaller than λ:
ICER =
Change in cost (SIPC) − change in cost (standard care)
Change in outcome (SIPC) − change in outcome (standard care)
. (1)
To understand the uncertainty around the ICERs, we produced the estimated differences in formal
care cost and outcomes by bootstrapping with 1000 replications. Regression approach was used to
predict the difference in costs and outcomes: the generalised linear model with a log-link function and
the Poisson distribution for cost due to the skewed distribution, and ordinary least squares regressions
for EQ-5D index score and IPOS Neuro-S8, after examining the distributions and model specifications.
In each regression, baseline values were controlled for. Bootstrapping was conducted using complete
cases only. These replications were plotted in cost-effectiveness planes. These planes have four quadrants
and combine changes in costs and changes in outcomes: (1) north-east (SIPC is more effective and more
costly); (2) north-west (SIPC is less effective and more costly); (3) south-west (SIPC is less effective and
less costly); and (4) south-west (SIPC is less costly and more effective).82 We examined the distribution of
1000 replications on the planes by four quadrants.
Finally, to account for the joint uncertainty of costs and outcomes, we conducted further analysis of
the probability of SIPC being cost-effective with a set of WTP thresholds, as well as calculating the
incremental net monetary benefit (INMB) of SIPC compared with standard care (details in Appendix 3).
Qualitative methods
Embedded within the trial was a qualitative component conducted concurrently,83 to explore which
aspects of SIPC were most valued or had most impact on patients’ and caregivers’ experiences of care,
how the change process of SIPC may be working and how the intervention is delivered in practice.
The intention was to form a theoretical model of SIPC to inform implementation requirements and
processes, and intended outcomes. The embedded qualitative study involved patients, caregivers and
health-care staff.
Patient and caregivers
Individual interviews were conducted with participants who received SIPC (at 12 weeks for the intervention
group and 24 weeks for the standard care group).We estimated a sample size in each study site of seven
patients/caregivers, totalling 35 patients/caregivers.We sought to conduct maximum variation sampling
to encompass the conditions eligible for inclusion in the trial. However, given that the trial sample largely
comprised MS and IPD patients, this was not practical, and purposive sampling was used. Only participants
who had indicated their consent to participate in these qualitative interviews at the initial trial consenting
stage were contacted regarding these interviews. Interviews were conducted in participants’ own homes
with patients, and caregivers when available, or with caregivers when patients lacked capacity to participate.
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The interviews were conducted by researchers and research nurses trained in and supervised during
qualitative interviews.When possible, a researcher who was not involved in the main trial data collection
conducted the interview to minimise the risk of unblinding.
Health-care staff
Focus groups were conducted with health-care staff from the respective centres to explore perceptions
of SIPC, processes of SIPC delivery and the local context of service delivery models for patients with
neurological conditions. We estimated a sample size of six service providers from each site, totalling
30 providers. Participants were identified by the local research teams for the central King’s College
London team, who e-mailed invitations to participate. Eligible participants comprised health professionals
involved in delivering the intervention in the respective study site (e.g. specialist nurses, neurologists, allied
health professionals). Each group comprised representatives from the respective centres and disciplines
involved in the care provision.When individual attendance at a focus group was not possible (e.g. clinical
commitments), individual interviews were conducted (either face to face or by telephone) to ensure
representation from all centres. The groups were facilitated by a researcher experienced in qualitative
research methods and an observer to document, for example, group processes and interactions.
All participants provided written informed consent.
Data analysis
Interviews and focus groups were digitally recorded, transcribed verbatim and anonymised prior to
analysis. Data analysis drew on Coffey and Atkinson’s84 iterative approach of coding and describing the
data, generating categories, through to forming hypotheses and generating theory. We explored the
impact of SIPC at three main levels (people and context, processes and tasks, and underpinning
theory)85 and sought to identify ways to enhance SIPC and the processes for wider implementation.
The analysis approach emphasised theory generation by asking questions about the data and
developing emergent lines of thinking to form and question emergent hypotheses. NVivo 11 software
(QSR International, Warrington, UK) for qualitative analysis was used for data storage, coding, searching
and retrieving, and recording analytical thinking. Quality appraisal sought to ensure systematic and
rigorous attention to analysis and reporting by, for example, holding supervisory review meetings to
consider the data analysis and emerging findings (held by CE and NH), attention to divergent cases and
use of qualitative research software to assist comprehensive reporting, auditability and transparency of
the findings.
Patient and public involvement
Patient and public involvement has been an integral part of all our research processes. An independent
PPI group was set up specifically for OPTCARE Neuro, comprising both patients and caregivers
with lived experience of MS, IPD, MSA and MND. The group advised on the application for ethics
approval and the development of all participant materials, as well as the delivery of the trial and the
interpretation of the findings. We engaged with our PPI members on multiple levels but predominantly
through 3-monthly face-to-face meetings at which we benefited from the expert views of our members
to help us prioritise the research questions and ensure that the study was undertaken in a way that
was meaningful and relevant to both patients and caregivers. A member of our PPI group was a
co-applicant on the funding application and an active member of the Study Steering Committee.
We had PPI representation in the Data Monitoring and Ethics Committee, which had oversight and
responsibility for the conduct of the trial. We actively involved our PPI members in the interpretation
of data, particularly the qualitative components of the study. This provided the study team with valuable
insight to understand the data and their relevance for addressing the needs of this patient population.
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Engagement
Engagement took place throughout the study. First, charities and patient societies supported and
publicised the trial in order to improve recruitment and dissemination. Specifically, the PSP Association,
the MS Society and Parkinson’s UK, which all featured details of the trial on their research web pages.
The trial was also featured in an issue of the Multiple Sclerosis Trust’s Way Ahead magazine for MS
health professionals, and in the PSP Association’s PSP Matters magazine, with two trial participants
contributing to the article. In May 2016, the study team hosted a 2-day workshop and conference on
palliative care in neurology. The first of these days was a closed meeting for OPTCARE Neuro teams,
with representation from principal investigators, research nurses, clinicians and PPI members from all
trial centres. A representative from each site gave a brief overview of local progress, and our PPI
group also presented on their involvement. It was extremely productive to have all the teams together
to exchange ideas and learn from each other. The second day was a conference that focused on clinical
components of palliative care for patients with LTNCs, and some interim data from the mapping
exercise and survey for professionals were presented. The conference had > 100 registrations and was
attended by a mixture of clinicians, researchers, students, PPI members and representatives from
charitable organisations and patient societies. The great turnout for the conference and the interest
from the audience members highlighted the importance of the OPTCARE Neuro work. Last,
throughout the course of the study, we have circulated 6-monthly newsletters to our study contacts,
which included palliative care and neurology clinicians, academics, researchers and charities.
Ethics approval and research governance
The trial was conducted in compliance with the principles of the Declaration of Helsinki (2013)86 and
the principles of Good Clinical Practice and in accordance with all applicable regulatory requirements,
including, but not limited to, the Research Governance Framework and the Mental Capacity Act
2005.62 The protocol and related documents were submitted for review and approved by the London
South East Research Ethics Committee (14/LO/1765).
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Centres varied in size of catchment areas (39–5840 square miles) and population served
(142,000–3,500,000). Neurology and specialist palliative care were often not co-terminous. Service
provision for neurology and specialist palliative care also varied; for example, neurology services varied
in the number and type of clinics provided, and palliative care services varied in the settings in which
they worked. The integration between neurology and palliative care teams varied between centres,
but more clearly between diseases. For MS, the integration was limited, with most centres having no
formal links. Only two centres broke this trend; one held an 8-weekly multidisciplinary team (MDT)
meeting, in which both MS and palliative care teams participated, and the other held a 3-monthly
complex problem clinic with palliative care attendance. For MND, a different picture emerged of
stronger integration. Most centres either held joint clinics or had a palliative care presence at MDT
meetings. At one site, all MND patients were invited to clinics at the local hospice; whereas at another,
all patients received a palliative care assessment. Good informal links were reported in one site where
the MND and palliative care nurses shared an office, but there were with no joint visits. The least
integrated site had no joint clinics and referrals were based on needs. Last, in Parkinson’s disease-
related disorders the integration was very mixed. Approximately half of the centres had no joint clinics
or formal relationships. Others had 2- to 3-monthly clinics or MDT meetings, with one site having a
palliative care presence at weekly clinics. There was a difference between the subsets of diseases, with
greater integration for MSA and PSP. The number of neurology patients per annum receiving specialist
palliative care reflected these differences in integration (a range of 9–88 patients with MND, a range
of 3–5 patients with Parkinson’s disease-related disorders and a range of 0–5 patients with MS).
Survey results
Parts of the text have been reproduced from Hepgul et al.56 This is an Open Access article distributed
in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original
work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
The survey received responses from 33 neurology and 26 palliative care professionals (20% response
rate). Two-thirds of respondents in both groups had > 10 years of experience in their respective fields.
Current levels of collaboration between the two specialties were reported to be ‘good/excellent’ by
36% of neurology professionals and by 58% of palliative care professionals. However, nearly half (45%) of
neurology compared with only 12% of palliative care professionals rated current levels of collaboration
‘poor/none’. When asked if there were any particular disease areas for which links were better, both groups
reported stronger links for MND. In addition, both professional groups felt that the new SIPC service being
trialled would influence future collaborations for the better (65–70% in both groups). Participants were
also asked what they thought would be the main barriers for the new SIPC service. The most common
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barriers identified by neurologists were resources, clinician awareness of services offered, continuing
collaborations, and communication between teams beyond the trial and geographical limitations. Similarly,
palliative care professionals also identified resources and clinician awareness of services offered (and
importantly the appropriateness of referrals they may receive) as barriers. However, the key barrier they
identified was that there may be a possible need for longer-term care beyond that offered by the SIPC
service. They also drew attention to patients’ perceptions of palliative care as a potential barrier.
Randomised trial results
Participant flow
Recruitment began in three centres in April 2015. Two centres opened in July 2015 and November
2015, with an additional two centres opening in February 2016 and September 2016. The total
recruitment period was 31 months, ending in November 2017, with all follow-up visits completed in
May 2018. One centre, Sheffield, was opened but failed to sustain recruitment and therefore was
closed. Other centres’ recruited numbers were broadly reflective of their catchment areas and local
populations. Monthly recruitment rates over the course of the recruitment period are presented in
Appendix 1. The trial recruited 350 patients living with a LTNC, plus 229 caregivers, with 176 patients
in the immediate SIPC intervention arm and 174 in the standard care waiting list control arm. Table 1
details the screening and enrolment by each site and Figure 1 outlines the participant flow up to the
primary end point of 12 weeks post randomisation.
Participant characteristics by trial arm
The baseline characteristics of the sample are presented in Tables 2 and 3 by trial arm. The groups are
comparable, except for patient ethnicity, with more patients of ethnicity other than white in the SIPC
group (13%) than in the standard care group (5%).




TotalLondon Liverpool Nottingham Cardiff Brighton Ashford Sheffield






Referred 158 69 100 67 71 64 6 535
Not in catchment
area
8 1 1 1 5 0 0 16
Already receiving
palliative care
11 2 0 1 1 6 0 21
Lacks capacity
and no caregiver
1 0 0 1 0 1 0 3
Not meeting
diagnostic criteria
2 0 0 0 0 1 0 3
Declined 25 16 19 22 15 12 3 112
Other 11 2 4 6 0 7 0 30
Enrolled patients
(caregivers)
100 (79) 48 (37) 76 (32) 36 (23) 50 (31) 37 (26) 3 (1) 350 (229)
RESULTS














• Lost to follow-up, n = 11
    • Deaths, n = 4
    • Withdrawals, n = 7
• Lost to follow-up, n = 3
    • Deaths, n = 1
    • Withdrawals, n = 2
• Lost to follow-up, n = 2
    • Deaths, n = 1
    • Withdrawals, n = 1
• Lost to follow-up, n = 7
    • Deaths, n = 2
    • Withdrawals, n = 5
Analysed (n = 176) (using
multiple imputation)








































FIGURE 1 Consolidated Standards of Reporting Trials (CONSORT) diagram showing the flow of participants. Reproduced
with permission from Gao et al.87 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The figure
includes minor additions and formatting changes to the original figure.
TABLE 2 Patient sociodemographic and clinical characteristics
Variable Value All SIPC
Standard
care
N 350 176 174
Age (years), mean (SD) 66.8 (11.8) 67.3 (10.9) 66.4 (12.6)
Gender, n (%) Man 179 (51.1) 86 (48.9) 93 (53.5)
Woman 171 (48.9) 90 (51.1) 81 (46.6)
Marital status, n (%) Single 35 (10.0) 16 (9.1) 19 (10.9)
Widowed 38 (10.9) 19 (10.8) 19 (10.9)
Married/civil partner 231 (66.0) 114 (64.8) 117 (67.2)
Divorced/separated 44 (12.6) 26 (14.8) 18 (10.3)
Not done/unknown 2 (0.6) 1 (0.6) 1 (0.6)
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TABLE 2 Patient sociodemographic and clinical characteristics (continued )
Variable Value All SIPC
Standard
care
Living status, n (%) Alone 65 (18.6) 35 (19.9) 30 (17.2)
With spouse/partner and/or children 244 (69.7) 125 (71.0) 119 (68.4)
With friend(s)/with others 41 (11.7) 16 (9.1) 25 (14.4)
Education, n (%) No formal education up to lower secondary school 139 (39.7) 67 (38.1) 72 (41.4)
Upper secondary to post-secondary vocational
qualification
116 (33.1) 53 (30.1) 63 (36.2)
Tertiary education 91 (26.0) 55 (31.3) 36 (20.7)
Not done/missing 4 (1.1) 1 (0.6) 3 (1.7)
Ethnicity, n (%) White 316 (90.3) 166 (94.3) 150 (86.2)
Other ethnic group 32 (9.1) 9 (5.1) 23 (13.2)
Employment, n (%) No 340 (97.1) 173 (98.3) 167 (96.0)
Yes 10 (2.9) 3 (1.7) 7 (4.0)
Feelings towards
income, n (%)
Living comfortably on present income 118 (33.7) 58 (33.0) 60 (34.5)
Coping on present income 162 (46.3) 85 (48.3) 77 (44.3)
Difficult on present income 24 (6.9) 12 (6.8) 12 (6.9)
Very difficult on present income 14 (4.0) 7 (4.0) 7 (4.0)
Not done/unknown 32 (9.1) 14 (8.0) 18 (10.3)
Diagnosis, n (%) MS 148 (42.3) 74 (42.1) 74 (42.5)
IPD 140 (40.0) 71 (40.3) 69 (39.7)
MSA 12 (3.4) 7 (4.0) 5 (2.9)
PSPa 27 (7.7) 13 (7.4) 14 (8.1)
MND 23 (6.6) 11 (6.3) 12 (6.9)
Years since diagnosis
Mean (SD) 12.3 (10.6) 12.3 (10.8) 12.4 (10.4)
Range 0–56 0–56 0–46
Comorbidities, n (%) No 99 (28.3) 42 (23.9) 57 (32.8)
Yes 251 (71.7) 134 (76.1) 117 (67.2)
Patient capacity, n (%) Consent 311 (88.9) 157 (89.2) 154 (88.5)
Personal consultee assent 39 (11.1) 19 (10.8) 20 (11.5)
AKPS, n (%) Totally bedfast 7 (2.0) 3 (1.7) 4 (2.3)
Almost completely bedfast 10 (2.9) 5 (2.8) 5 (2.9)
In bed > 50% of the time 21 (6.0) 10 (5.7) 11 (6.3)
Requires considerable assistance 170 (48.6) 77 (43.8) 93 (53.5)
Requires occasional assistance 98 (28.0) 54 (30.7) 44 (25.3)
Cares for self 33 (9.4) 19 (10.8) 14 (8.1)
Normal activity with effort 9 (2.6) 7 (4.0) 2 (1.2)
Not available/applicable 1 (0.3) 1 (0.6) 0
Not done 1 (0.3) 0 1 (0.6)
a Includes two patients with corticobasal degeneration.
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Primary analysis of effectiveness
Point estimates and adjusted analyses, using multiply imputed data for the entire sample (n = 350), are
presented in Table 4. There were no statistically significant differences between the trial arms for either
the primary outcome or any of the secondary outcomes. The primary outcome (IPOS Neuro-S8) fell in
both groups between baseline and 12 weeks, with a greater fall (i.e. improvement) in the SIPC group
than in the standard care group (–0.78 vs. –0.28). This pattern was consistent for most secondary
outcomes. Of note, for some secondary outcomes (indicated with table footnote c), lower scores indicate
poorer outcomes. The missing data for the primary outcome due to withdrawal or unknown reasons
were 4% at 12 weeks.
Sensitivity analysis 1
Imputed data for the entire sample adjusted for ethnicity are presented in Table 5. These estimates
are consistent with those from the primary analyses, in favour of the SIPC arm, although not
statistically significant.
TABLE 3 Caregiver sociodemographic characteristics
Variable Value All SIPC
Standard
care
N 229 121 108
Age (years), mean (SD) 64.2 (13.3) 63.3 (13.3) 65.3 (13.4)
Gender, n (%) Man 81 (35.4) 41 (33.9) 40 (37.0)
Woman 148 (64.6) 80 (66.1) 68 (63.0)
Marital status, n (%) Single 14 (6.1) 7 (5.8) 7 (6.5)
Widowed 10 (4.4) 4 (3.3) 6 (5.6)
Married/civil partner 200 (87.3) 109 (90.1) 91 (84.3)
Divorced/separated 5 (2.2) 1 (0.8) 4 (3.7)
Living status, n (%) Alone 9 (3.9) 4 (3.3) 5 (4.6)
With spouse/partner and/or children 200 (87.3) 109 (90.1) 91 (84.3)
With friends/with others 20 (8.7) 8 (6.6) 12 (11.1)
Relationship to
patient, n (%)
Spouse/partner 177 (77.3) 97 (80.2) 80 (74.1)
Son/daughter 29 (12.7) 17 (14.1) 12 (11.1)
Other 23 (10.0) 0 4 (3.7)
Education, n (%) No formal education up to lower secondary school 96 (41.9) 51 (42.2) 45 (41.7)
Upper secondary school to post-secondary
vocational qualification
66 (28.8) 37 (30.6) 29 (26.9)
Tertiary education 62 (27.1) 30 (24.8) 32 (29.6)
Not done/missing 5 (2.2) 3 (2.5) 2 (1.9)
Ethnicity, n (%) White 211 (92.1) 113 (93.4) 98 (90.7)
Other ethnic group 18 (7.9) 8 (6.6) 10 (9.3)
Employment, n (%) No 162 (70.7) 86 (71.1) 76 (70.4)
Yes 67 (29.3) 35 (28.9) 32 (29.6)
Illness, n (%) No 77 (33.6) 41 (33.9) 36 (33.3)
Yes 140 (61.1) 70 (57.9) 70 (64.8)
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TABLE 4 Means and change scores of primary (95% CI) and secondary outcomes (99.55% CI) at baseline and 12 weeks
post randomisation, by trial arm, using multiply imputed data from all recruited patients






Baseline 6.93 (6.48 to 7.37) 6.89 (6.24 to 7.54) 6.96 (6.34 to 7.58)
12 weeks 6.40 (5.93 to 6.86) 6.11 (5.46 to 6.77) 6.68 (6.02 to 7.34)




Baseline 26.92 (25.14 to 28.71) 26.69 (24.23 to 29.15) 27.16 (24.57 to 29.75)
12 weeks 25.50 (23.60 to 27.40) 24.74 (22.10 to 27.37) 26.27 (23.58 to 28.96)
Change score –1.42 (–3.20 to 0.35) –1.95 (–4.38 to 0.48) –0.89 (–3.15 to 1.36) 0.22
IPOS Neuro-8,
x (CI)
Baseline 11.51 (10.49 to 12.53) 11.43 (10.07 to 12.79) 11.58 (10.09 to 13.08)
12 weeks 11.19 (10.13 to 12.24) 10.59 (9.09 to 12.09) 11.80 (10.34 to 13.26)
Change score –0.32 (–1.32 to 0.69) –0.84 (–2.09 to 0.40) 0.21 (–1.25 to 1.68) 0.06
IPOS Neuro,
x (CI)
Baseline 47.04 (42.49 to 51.59) 47.36 (41.94 to 52.78) 46.72 (40.93 to 52.51)
12 weeks 43.68 (37.74 to 49.61) 43.14 (35.28 to 51.00) 44.22 (37.55 to 50.89)
Change score –3.36 (–8.41 to 1.68) –4.22 (–10.87 to 2.43) –2.50 (–8.37 to 3.37) 0.53
HADS anxiety,
x (CI)
Baseline 7.64 (6.95 to 8.34) 7.78 (6.78 to 8.77) 7.51 (6.52 to 8.50)
12 weeks 7.51 (6.70 to 8.32) 7.43 (6.28 to 8.58) 7.59 (6.53 to 8.66)
Change score –0.13 (–0.68 to 0.42) –0.35 (–1.12 to 0.43) 0.08 (–0.65 to 0.81) 0.27
HADS depression,
x (CI)
Baseline 8.22 (7.61 to 8.84) 8.13 (7.29 to 8.97) 8.31 (7.47 to 9.16)
12 weeks 8.09 (7.44 to 8.74) 7.96 (7.03 to 8.88) 8.22 (7.35 to 9.09)
Change score –0.13 (–0.58 to 0.32) –0.17 (–0.79 to 0.45) –0.09 (–0.78 to 0.59) 0.69
EQ-5D VAS,c
x (CI)
Baseline 52.49 (48.91 to 56.07) 52.72 (47.91 to 57.53) 52.25 (47.01 to 57.49)
12 weeks 52.23 (48.29 to 56.16) 53.69 (48.03 to 59.34) 50.75 (45.36 to 56.14)
Change score –0.26 (–4.87 to 4.35) 0.97 (–5.01 to 6.94) –1.50 (–8.05 to 5.05) 0.27
SEMCD Scale,c
x (CI)
Baseline 5.26 (4.90 to 5.62) 5.39 (4.89 to 5.89) 5.13 (4.63 to 5.64)
12 weeks 5.11 (4.74 to 5.48) 5.28 (4.75 to 5.82) 4.94 (4.41 to 5.47)
Change score –0.15 (–0.52 to 0.22) –0.10 (–0.60 to 0.40) –0.19 (–0.70 to 0.31) 0.37
FAMCARE-P16,c
x (CI)
Baseline 50.32 (47.92 to 52.72) 50.33 (46.66 to 54.00) 50.30 (47.08 to 53.53)
12 weeks 47.75 (44.81 to 50.69) 48.08 (43.75 to 52.41) 47.41 (43.52 to 51.31)
Change score –2.57 (–5.12 to –0.03) –2.26 (–6.05 to 1.53) –2.89 (–6.23 to 0.45) 0.70
Secondary caregiver outcomesb
ZBI-12,c x (CI) Baseline 18.46 (16.57 to 20.35) 18.25 (15.59 to 20.90) 18.68 (16.28 to 21.08)
12 weeks 18.76 (16.81 to 20.71) 18.60 (15.93 to 21.27) 18.92 (16.28 to 21.55)
Change score 0.30 (–0.68 to 1.27) 0.35 (–0.98 to 1.68) 0.24 (–1.15 to 1.64) 0.90
ZBI positivity,c
x (CI)
Baseline 18.85 (17.66 to 20.03) 18.97 (17.36 to 20.59) 18.72 (17.05 to 20.38)
12 weeks 18.50 (17.11 to 19.88) 18.87 (17.08 to 20.67) 18.12 (16.15 to 20.10)
Change score –0.35 (–1.29 to 0.59) –0.10 (–1.43 to 1.23) –0.59 (–1.98 to 0.79) 0.40
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TABLE 4 Means and change scores of primary (95% CI) and secondary outcomes (99.55% CI) at baseline and 12 weeks
post randomisation, by trial arm, using multiply imputed data from all recruited patients (continued )





Baseline 53.89 (50.79 to 56.99) 53.81 (49.64 to 57.97) 53.98 (49.93 to 58.02)
12 weeks 53.61 (49.78 to 57.44) 53.99 (48.92 to 59.07) 53.23 (48.38 to 58.07)
Change score –0.28 (–3.47 to 2.91) 0.19 (–4.86 to 5.23) –0.75 (–4.64 to 3.14) 0.67
VAS, visual analogue scale.
a p-value for two-group comparisons using GLMM, adjusting for baseline score with centre modelled as a
random effect.
b 99.55% CIs, Bonferroni correction to control for multiple testing (adjusted alpha = 0.0045, 0.05/11).
c Lower scores indicate poorer outcomes.
TABLE 5 Means and change scores of primary (95% CI) and secondary outcomes (99.55% CI) at baseline and 12 weeks
post randomisation, by trial arm, using multiply imputed data from all recruited patients and adjusting for ethnicity






Baseline 6.93 (6.48 to 7.37) 6.89 (6.24 to 7.54) 6.96 (6.34 to 7.58)
12 weeks 6.40 (5.93 to 6.86) 6.11 (5.46 to 6.77) 6.68 (6.02 to 7.34)




Baseline 26.92 (25.69 to 28.15) 26.69 (24.99 to 28.38) 27.16 (25.38 to 28.94)
12 weeks 25.50 (24.19 to 26.80) 24.74 (22.92 to 26.55) 26.27 (24.42 to 28.12)
Change score –1.42 (–2.64 to –0.21) –1.95 (–3.60 to –0.30) –0.89 (–2.45 to 0.66) 0.25
IPOS Neuro-S8,
x (CI)
Baseline 11.51 (10.80 to 12.21) 11.43 (10.49 to 12.37) 11.58 (10.55 to 12.62)
12 weeks 11.19 (10.46 to 11.92) 10.59 (9.55 to 11.62) 11.80 (10.79 to 12.80)
Change score –0.32 (–1.01 to 0.37) –0.84 (–1.70 to 0.01) 0.21 (–0.79 to 1.22) 0.07
IPOS Neuro,
x (CI)
Baseline 47.04 (43.96 to 50.12) 47.36 (43.66 to 51.06) 46.72 (42.78 to 50.65)
12 weeks 43.68 (39.69 to 47.66) 43.14 (37.85 to 48.43) 44.22 (39.69 to 48.75)
Change score –3.36 (–6.74 to 0.02) –4.22 (–8.68 to 0.24) –2.50 (–6.48 to 1.48) 0.56
HADS anxiety,
x (CI)
Baseline 7.64 (7.16 to 8.13) 7.78 (7.09 to 8.46) 7.51 (6.83 to 8.19)
12 weeks 7.51 (6.96 to 8.07) 7.43 (6.64 to 8.22) 7.59 (6.86 to 8.33)
Change score –0.13 (–0.51 to 0.25) –0.35 (–0.88 to 0.19) 0.08 (–0.42 to 0.59) 0.28
HADS depression,
x (CI)
Baseline 8.22 (7.80 to 8.64) 8.13 (7.55 to 8.71) 8.31 (7.73 to 8.90)
12 weeks 8.09 (7.64 to 8.54) 7.96 (7.32 to 8.59) 8.22 (7.62 to 8.82)
Change score –0.13 (–0.44 to 0.18) –0.17 (–0.60 to 0.25) –0.09 (–0.56 to 0.38) 0.70
EQ-5D VAS,c
x (CI)
Baseline 52.49 (50.02 to 54.96) 52.72 (49.40 to 56.04) 52.25 (48.64 to 55.86)
12 weeks 52.23 (49.52 to 54.93) 53.69 (49.79 to 57.58) 50.75 (47.04 to 54.46)
Change score –0.26 (–3.43 to 2.91) 0.97 (–3.15 to 5.08) –1.50 (–6.00 to 3.00) 0.31
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Sensitivity analysis 2
Imputed estimates for primary and secondary outcomes for all patients, excluding two who were
identified as ineligible for the trial post randomisation (n = 348), are presented in Table 6. These
estimates are again consistent with the primary analyses and have the same pattern.
TABLE 5 Means and change scores of primary (95% CI) and secondary outcomes (99.55% CI) at baseline and 12 weeks
post randomisation, by trial arm, using multiply imputed data from all recruited patients and adjusting for ethnicity
(continued )





Baseline 5.26 (5.01 to 5.51) 5.39 (5.04 to 5.73) 5.13 (4.78 to 5.48)
12 weeks 5.11 (4.86 to 5.37) 5.28 (4.91 to 5.66) 4.94 (4.58 to 5.30)
Change score –0.15 (–0.40 to 0.11) –0.10 (–0.45 to 0.25) –0.19 (–0.54 to 0.15) 0.38
FAMCARE-P16,c
x (CI)
Baseline 50.32 (48.66 to 51.97) 50.33 (47.80 to 52.86) 50.30 (48.08 to 52.52)
12 weeks 47.75 (45.72 to 49.77) 48.08 (45.10 to 51.06) 47.41 (44.73 to 50.10)
Change score –2.57 (–4.32 to –0.82) –2.26 (–4.87 to 0.36) –2.89 (–5.19 to –0.59) 0.78
Secondary caregiver outcomesb
ZBI-12, x (CI) Baseline 18.46 (17.17 to 19.75) 18.25 (16.43 to 20.06) 18.68 (17.03 to 20.32)
12 weeks 18.76 (17.42 to 20.09) 18.60 (16.77 to 20.43) 18.92 (17.11 to 20.72)
Change score 0.30 (–0.37 to 0.96) 0.35 (–0.56 to 1.26) 0.24 (–0.72 to 1.20) 0.87
ZBI positivity,c
x (CI)
Baseline 18.85 (18.03 to 19.66) 18.97 (17.87 to 20.08) 18.72 (17.57 to 19.86)
12 weeks 18.50 (17.55 to 19.45) 18.87 (17.64 to 20.10) 18.12 (16.77 to 19.47)
Change score –0.35 (–0.99 to 0.30) –0.10 (–1.01 to 0.81) –0.59 (–1.54 to 0.35) 0.38
FAMCARE 2,c
x (CI)
Baseline 53.89 (51.77 to 56.01) 53.81 (50.95 to 56.67) 53.98 (51.21 to 56.74)
12 weeks 53.61 (51.01 to 56.21) 53.99 (50.52 to 57.46) 53.23 (49.92 to 56.53)
Change score –0.28 (–2.47 to 1.91) 0.19 (–3.25 to 3.63) –0.75 (–3.43 to 1.92) 0.67
VAS, visual analogue scale.
a p-value for two-group comparisons using GLMM, adjusting for baseline score and ethnicity with centre modelled as
a random effect.
b 99.55% CIs, Bonferroni correction to control for multiple testing (adjusted alpha= 0.0045, 0.05/11).
c Lower scores indicate poorer outcomes.
TABLE 6 Means and change scores of primary (95% CI) and secondary outcomes (99.55% CI) at baseline and 12 weeks
post randomisation, by trial arm, using multiply imputed patient data, excluding two ineligible patients






Baseline 6.93 (6.45 to 7.40) 6.83 (6.16 to 7.50) 7.02 (6.39 to 7.65)
12 weeks 6.41 (5.94 to 6.88) 6.07 (5.42 to 6.71) 6.76 (6.07 to 7.45)
Change score –0.51 (–0.94 to –0.09) –0.77 (–1.37 to –0.16) –0.26 (–0.81 to 0.29) 0.12
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TABLE 6 Means and change scores of primary (95% CI) and secondary outcomes (99.55% CI) at baseline and 12 weeks
post randomisation, by trial arm, using multiply imputed patient data, excluding two ineligible patients (continued )






Baseline 26.89 (25.64 to 28.13) 26.61 (24.90 to 28.32) 27.17 (25.48 to 28.86)
12 weeks 25.45 (24.17 to 26.73) 24.64 (23.00 to 26.28) 26.27 (24.38 to 28.17)
Change score –1.44 (–2.44 to –0.44) –1.97 (–3.31 to –0.63) –0.90 (–2.46 to 0.66) 0.25
IPOS Neuro-S8,
x (CI)
Baseline 11.48 (10.79 to 12.17) 11.52 (10.55 to 12.49) 11.44 (10.43 to 12.45)
12 weeks 11.18 (10.44 to 11.93) 10.72 (9.62 to 11.83) 11.65 (10.68 to 12.61)
Change score –0.30 (–0.95 to 0.35) –0.80 (–1.72 to 0.12) 0.21 (–0.66 to 1.08) 0.11
IPOS Neuro,
x (CI)
Baseline 47.51 (44.19 to 50.83) 47.47 (43.09 to 51.86) 47.55 (43.62 to 51.48)
12 weeks 43.30 (39.92 to 46.67) 42.53 (38.25 to 46.81) 44.07 (39.70 to 48.44)
Change score –4.21 (–7.54 to –0.89) –4.94 (–9.39 to –0.49) –3.48 (–7.95 to 0.99) 0.59
HADS anxiety,
x (CI)
Baseline 7.71 (7.22 to 8.20) 7.81 (7.11 to 8.50) 7.61 (6.93 to 8.30)
12 weeks 7.62 (7.07 to 8.17) 7.50 (6.70 to 8.30) 7.75 (7.03 to 8.46)
Change score –0.09 (–0.47 to 0.29) –0.31 (–0.82 to 0.21) 0.13 (–0.37 to 0.64) 0.25
HADS depression,
x (CI)
Baseline 8.23 (7.82 to 8.64) 8.14 (7.55 to 8.72) 8.33 (7.76 to 8.89)
12 weeks 8.07 (7.59 to 8.54) 7.91 (7.24 to 8.58) 8.23 (7.60 to 8.86)
Change score –0.16 (–0.51 to 0.19) –0.23 (–0.71 to 0.25) –0.09 (–0.58 to 0.39) 0.57
EQ-5D VAS,c
x (CI)
Baseline 52.76 (50.26 to 55.26) 53.14 (49.73 to 56.55) 52.37 (48.76 to 55.98)
12 weeks 51.98 (49.13 to 54.83) 53.52 (49.57 to 57.46) 50.42 (46.56 to 54.28)
Change score –0.78 (–3.88 to 2.32) 0.37 (–4.17 to 4.92) –1.95 (–6.11 to 2.20) 0.33
SEMCD Scale,c
x (CI)
Baseline 5.25 (5.00 to 5.50) 5.37 (5.01 to 5.72) 5.14 (4.77 to 5.50)
12 weeks 5.13 (4.87 to 5.39) 5.31 (4.95 to 5.66) 4.95 (4.57 to 5.32)
Change score –0.12 (–0.37 to 0.12) –0.06 (–0.41 to 0.29) –0.19 (–0.55 to 0.17) 0.35
FAMCARE-P16,c
x (CI)
Baseline 50.19 (48.48 to 51.91) 50.20 (47.74 to 52.67) 50.18 (47.78 to 52.59)
12 weeks 47.73 (45.69 to 49.77) 48.00 (45.14 to 50.85) 47.45 (44.57 to 50.33)
Change score –2.47 (–4.20 to –0.73) –2.21 (–4.74 to 0.32) –2.73 (–5.19 to –0.27) 0.83
Secondary caregiver outcomesb
ZBI-12, x (CI) Baseline 18.48 (17.21 to 19.74) 18.30 (16.69 to 19.90) 18.66 (16.83 to 20.49)
12 weeks 18.74 (17.34 to 20.15) 18.58 (16.77 to 20.40) 18.91 (16.96 to 20.86)
Change score 0.27 (–0.40 to 0.93) 0.28 (–0.60 to 1.17) 0.25 (–0.67 to 1.16) 0.95
ZBI positivity,c
x (CI)
Baseline 18.88 (18.00 to 19.76) 18.98 (17.85 to 20.11) 18.77 (17.50 to 20.05)
12 weeks 18.48 (17.54 to 19.43) 18.83 (17.59 to 20.08) 18.13 (16.85 to 19.41)
Change score –0.39 (–0.96 to 0.18) –0.15 (–1.01 to 0.71) –0.64 (–1.49 to 0.20) 0.34
FAMCARE 2,c
x (CI)
Baseline 53.79 (51.91 to 55.67) 54.05 (51.32 to 56.78) 53.53 (50.83 to 56.23)
12 weeks 53.32 (50.75 to 55.90) 53.95 (50.68 to 57.23) 52.68 (49.01 to 56.36)
Change score –0.47 (–2.81 to 1.88) –0.09 (–3.18 to 2.99) –0.84 (–3.94 to 2.25) 0.62
VAS, visual analogue scale.
a p-value for two-group comparisons using GLMM, adjusting for baseline score and ethnicity with centre modelled as
a random effect.
b 99.55% CIs, Bonferroni correction to control for multiple testing (adjusted alpha = 0.0045, 0.05/11).
c Lower scores indicate poorer outcomes.
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Sensitivity analysis 3
Estimates and analyses for complete patient cases are presented in Table 7. The sample size for those
patients who had complete data at both baseline and 12 weeks is reported for each outcome. These
sample sizes vary, as different outcomes had different numbers of missing data. Similar to the primary
analysis of effectiveness, there were no statistically significant differences between the trial arms for
TABLE 7 Means and change scores of primary (95% CI) and secondary outcomes (99.55% CI) at baseline and 12 weeks
post randomisation, by trial arm, using complete patient data for both baseline and week 12
Measure Time point All SIPC Standard care p-valuea
Primary outcome
IPOS Neuro-S8,
x (CI) (n = 270)
Baseline 6.85 (6.38 to 7.32) 6.68 (6.04 to 7.33) 7.01 (6.34 to 7.69)
12 weeks 6.31 (5.85 to 6.78) 5.90 (5.28 to 6.52) 6.72 (6.01 to 7.42)
Change score –0.54 (–0.91 to –0.16) –0.78 (–1.30 to –0.27) –0.30 (–0.84 to 0.24) 0.09
Secondary patient outcomesb
IPOS Neuro-S24,
x (CI) (n = 235)
Baseline 26.58 (24.68 to 28.48) 25.57 (22.94 to 28.20) 27.57 (24.80 to 30.35)
12 weeks 25.0 (23.03 to 26.96) 23.22 (20.70 to 25.74) 26.73 (23.75 to 29.72)
Change score –1.59 (–3.06 to –0.17) –2.35 (–4.00 to –0.70) –0.84 (–3.28 to 1.60) 0.032
IPOS Neuro,
x (CI) (n = 79)
Baseline 47.32 (41.35 to 53.28) 42.22 (34.53 to 49.92) 51.58 (42.70 to 60.46)
12 weeks 42.76 (36.21 to 49.31) 37.86 (28.88 to 46.85) 46.86 (37.31 to 56.41)
Change score –4.56 (–8.42 to –0.70) –4.36 (–8.45 to –0.27) –4.72 (–11.21 to 1.76) 0.80
IPOS Neuro-8,
x (CI) (n = 246)
Baseline 11.07 (9.98 to 12.16) 10.78 (9.36 to 12.20) 11.34 (9.66 to 13.01)
12 weeks 10.70 (9.62 to 11.77) 9.56 (8.11 to 11.01) 11.74 (10.17 to 13.31)
Change score –0.37 (–1.30 to 0.55) –1.22 (–2.47 to 0.03) 0.41 (–0.95 to 1.77) 0.001
HADS anxiety,
x (CI) (n = 275)
Baseline 7.45 (6.72 to 8.19) 7.39 (6.35 to 8.44) 7.51 (6.49 to 8.56)
12 weeks 7.33 (6.57 to 8.09) 6.95 (5.82 to 8.09) 7.67 (6.64 to 8.70)
Change score –0.13 (–0.64 to 0.39) –0.44 (–1.18 to 0.30) 0.16 (–0.56 to 0.88) 0.07
HADS depression,
x (CI) (n = 275)
Baseline 8.13 (7.51 to 8.74) 7.89 (6.99 to 8.79) 8.35 (7.49 to 9.21)
12 weeks 7.96 (7.32 to 8.60) 7.62 (6.65 to 8.60) 8.27 (7.42 to 9.13)
Change score –0.17 (–0.64 to 0.31) –0.27 (–0.92 to 0.39) –0.08 (–0.78 to 0.63) 0.33
EQ-5D VAS,c
x (CI) (n = 281)
Baseline 53.14 (49.42 to 56.86) 54.13 (49.03 to 59.23) 52.18 (46.68 to 57.68)
12 weeks 52.43 (48.71 to 56.16) 54.72 (49.34 to 60.10) 50.20 (44.99 to 55.41)
Change score –0.71 (–5.05 to 3.63) 0.59 (–5.63 to 6.81) –1.98 (–8.15 to 4.20) 0.11
SEMCD Scale,c
x (CI) (n = 274)
Baseline 5.34 (4.95 to 5.73) 5.56 (5.03 to 6.10) 5.12 (4.55 to 5.69)
12 weeks 5.22 (4.84 to 5.59) 5.50 (4.99 to 6.01) 4.93 (4.39 to 5.47)
Change score –0.13 (–0.47 to 0.22) –0.06 (–0.54 to 0.42) –0.19 (–0.69 to 0.31) 0.12
FAMCARE-P16,c
x (CI) (n = 193)
Baseline 53.11 (50.38 to 55.84) 54.05 (50.01 to 58.09) 52.18 (48.40 to 55.95)
12 weeks 52.79 (49.89 to 55.69) 54.82 (50.70 to 58.95) 50.77 (46.66 to 54.88)
Change score –0.32 (–3.16 to 2.51) 0.77 (–3.66 to 5.20) –1.40 (–5.05 to 2.25) 0.08
VAS, visual analogue scale.
a p-value for two-group comparisons using GLMM, adjusting for baseline score and ethnicity with centre modelled as
a random effect.
b 99.55% CIs, Bonferroni correction to control for multiple testing (adjusted alpha= 0.0045, 0.05/11).
c Lower scores indicate poorer outcomes.
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either the primary outcome or most of the secondary outcomes. The change scores for IPOS Neuro-8
(non-symptom items) were significantly different between the trial arms (p = 0.001), with a reduction
seen in the SIPC group and an increase in the standard care group. Furthermore, there was a similar
pattern of greater favourable change scores in the SIPC group than in the standard care group on
most outcomes.
Sensitivity analysis 4
Data from caregivers with complete data at both baseline and 12 weeks are presented in Table 8.
Results are available only for measures completed by caregivers. Again, there were no statistically
significant differences between the trial arms, but there was a pattern of greater, favourable change
scores in the SIPC group than in the standard care group on most outcomes.
TABLE 8 Means and change scores of primary (95% CI) and secondary outcomes (99.55% CI) at baseline and 12 weeks
post randomisation, by trial arm, using caregivers with complete data at both baseline and 12 weeks
Measure Time point All SIPC Standard care p-valuea
Primary outcome
IPOS Neuro-S8,
x (CI) (n= 175)
Baseline 7.19 (6.64 to 7.75) 7.37 (6.58 to 8.15) 7.01 (6.22 to 7.80)
12 weeks 6.20 (5.62 to 6.78) 6.14 (5.29 to 7.00) 6.26 (5.45 to 7.07)
Change score –0.99 (–1.46 to –0.53) –1.22 (–1.89 to –0.55) –0.75 (–1.39 to –0.11) 0.40
Secondary patient outcomesb
IPOS Neuro-S24,
x (CI) (n= 146)
Baseline 30.96 (28.65 to 33.27) 30.29 (27.18 to 33.40) 31.75 (28.16 to 35.33)
12 weeks 27.42 (24.74 to 30.10) 26.30 (22.30 to 30.30) 28.73 (25.16 to 32.31)
Change score –3.54 (–5.51 to –1.57) –3.99 (–6.80 to –1.18) –3.01 (–5.85 to –0.18) 0.34
IPOS Neuro,
x (CI) (n= 73)
Baseline 55.14 (48.77 to 61.50) 55.98 (47.06 to 64.89) 54.06 (44.19 to 63.94)
12 weeks 48.79 (42.10 to 55.49) 49.34 (39.70 to 58.98) 48.09 (38.12 to 58.07)
Change score –6.34 (–10.22 to –2.47) –6.63 (–12.63 to –0.64) –5.97 (–10.99 to –0.95) 0.87
IPOS Neuro-8,
x (CI) (n= 178)
Baseline 12.75 (11.62 to 13.87) 12.88 (11.26 to 14.50) 12.61 (11.00 to 14.22)
12 weeks 11.40 (10.17 to 12.63) 10.73 (9.01 to 12.44) 12.11 (10.32 to 13.91)




Baseline 18.95 (17.04 to 20.87) 18.62 (15.87 to 21.38) 19.29 (16.56 to 22.03)
12 weeks 19.31 (17.28 to 21.34) 19.11 (16.15 to 22.08) 19.52 (16.67 to 22.36)
Change score 0.36 (–0.66 to 1.37) 0.49 (–0.87 to 1.85) 0.22 (–1.33 to 1.77) 0.76
ZBI positivity,c
x (CI) (n= 193)
Baseline 19.03 (17.70 to 20.36) 19.34 (17.46 to 21.22) 18.70 (16.76 to 20.64)
12 weeks 18.63 (17.25 to 20.01) 19.37 (17.34 to 21.40) 17.83 (15.94 to 19.72)
Change score –0.40 (–1.42 to 0.62) 0.03 (–1.43 to 1.49) –0.87 (–2.32 to 0.58) 0.11
FAMCARE 2,c
x (CI) (n= 140)
Baseline 58.29 (55.32 to 61.27) 60.09 (55.81 to 64.37) 56.22 (52.06 to 60.37)
12 weeks 58.54 (55.52 to 61.57) 60.21 (55.97 to 64.45) 56.62 (52.22 to 61.01)
Change score 0.25 (–2.81 to 3.31) 0.12 (–4.50 to 4.74) 0.40 (–3.70 to 4.50) 0.34
a p-value for two-group comparisons using GLMM, adjusting for baseline score and ethnicity with centre modelled as
a random effect.
b 99.55% CIs, Bonferroni correction to control for multiple testing (adjusted alpha = 0.0045, 0.05/11).
c Lower scores indicate poorer outcomes.
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Sensitivity analysis 5
The fifth sensitivity analysis, in which complete patient data were used, when available, at both
baseline and 12 weeks, and proxy data were imputed if patient data were missing but caregiver data
were complete and available at both time points, is presented in Table 9. The results remain the same.
As seen in sensitivity analysis 3, only the between-group change score for IPOS Neuro 8 reached
statistical significance for two-group comparisons (p = 0.003).
Sensitivity analysis 6
The final sensitivity analysis, using multiply imputed data from patients with MS only, is presented in
Table 10. The results are consistent with previous analyses.
TABLE 9 Means and change scores of primary (95% CI) and secondary outcomes (99.55% CI) at baseline and 12 weeks
post randomisation, by trial arm, using patients with complete data at both baseline and 12 weeks plus imputed proxy
data if available at both baseline and 12 weeks
Measure Time point All SIPC Standard care p-valuea
Primary outcome
IPOS Neuro-S8,
x (CI) (n = 308)
Baseline 6.81 (6.38 to 7.25) 6.79 (6.18 to 7.40) 6.83 (6.20 to 7.46)
12 weeks 6.17 (5.74 to 6.61) 5.84 (5.26 to 6.43) 6.50 (5.85 to 7.15)
Change score –0.64 (–0.99 to –0.29) –0.95 (–1.44 to –0.46) –0.33 (–0.83 to 0.17) 0.05
Secondary outcomesb
IPOS Neuro-S24,
x (CI) (n = 278)
Baseline 27.74 (25.97 to 29.51) 27.11 (24.57 to 29.64) 28.37 (25.85 to 30.89)
12 weeks 25.85 (24.03 to 27.68) 24.53 (22.02 to 27.04) 27.17 (24.50 to 29.84)
Change score –1.88 (–3.22 to –0.55) –2.58 (–4.14 to –1.01) –1.19 (–3.39 to 1.00) 0.050
IPOS Neuro,
x (CI) (n = 120)
Baseline 51.19 (46.28 to 56.10) 51.11 (43.86 to 58.37) 51.27 (44.32 to 58.22)
12 weeks 46.66 (41.37 to 51.95) 46.33 (38.51 to 54.15) 47.00 (39.51 to 54.49)
Change score –4.53 (–7.67 to –1.40) –4.79 (–8.85 to –0.72) –4.27 (–9.26 to 0.72) 0.80
IPOS Neuro-8,
x (CI) (n = 290)
Baseline 11.50 (10.50 to 12.51) 11.51 (10.15 to 12.87) 11.50 (9.99 to 13.00)
12 weeks 10.91 (9.91 to 11.91) 10.12 (8.71 to 11.52) 11.68 (10.27 to 13.09)
Change score –0.59 (–1.44 to 0.26) –1.39 (–2.57 to –0.21) 0.18 (–1.03 to 1.40) 0.003
a p-value for two-group comparisons using GLMM, adjusting for baseline score and ethnicity with centre modelled as
a random effect.
b 99.55% CIs, Bonferroni correction to control for multiple testing (adjusted alpha= 0.0045, 0.05/11).
TABLE 10 Means and change scores of primary (95% CI) and secondary outcomes (99.55% CI) at baseline and 12 weeks
post randomisation by trial arm, using multiply imputed data from patients with MS only




Baseline 7.09 (6.42 to 7.75) 7.08 (6.07 to 8.09) 7.10 (6.24 to 7.96)
12 weeks 6.30 (5.56 to 7.05) 6.25 (5.19 to 7.31) 6.35 (5.32 to 7.38)
Change score –0.79 (–1.33 to –0.24) –0.83 (–1.66 to 0.00) –0.75 (–1.49 to 0.00) 0.88
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TABLE 10 Means and change scores of primary (95% CI) and secondary outcomes (99.55% CI) at baseline and 12 weeks
post randomisation by trial arm, using multiply imputed data from patients with MS only (continued )




Baseline 27.67 (24.85 to 30.50) 27.61 (23.51 to 31.71) 27.74 (24.18 to 31.31)
12 weeks 24.84 (21.71 to 27.97) 24.70 (20.63 to 28.76) 24.98 (20.53 to 29.43)
Change score –2.84 (–5.63 to –0.04) –2.91 (–6.41 to 0.59) –2.76 (–6.63 to 1.11) 0.90
IPOS Neuro-8,
x (CI)
Baseline 11.07 (9.32 to 12.82) 10.75 (8.25 to 13.26) 11.38 (8.97 to 13.80)
12 weeks 10.30 (8.65 to 11.96) 9.69 (7.32 to 12.06) 10.91 (8.54 to 13.29)
Change score –0.77 (–2.26 to 0.73) –1.06 (–3.20 to 1.07) –0.47 (–2.35 to 1.41) 0.37
IPOS Neuro,
x (CI)
Baseline 47.51 (38.16 to 56.87) 48.13 (36.51 to 59.75) 46.90 (36.76 to 57.04)
12 weeks 43.69 (35.38 to 52.00) 43.56 (31.56 to 55.56) 43.83 (34.14 to 53.51)
Change score –3.82 (–12.08 to 4.43) –4.58 (–14.59 to 5.44) –3.07 (–14.09 to 7.95) 0.79
HADS anxiety,
x (CI)
Baseline 7.26 (6.12 to 8.40) 7.48 (5.88 to 9.07) 7.04 (5.43 to 8.66)
12 weeks 6.88 (5.72 to 8.04) 6.78 (5.07 to 8.49) 6.98 (5.41 to 8.54)
Change score –0.38 (–1.17 to 0.41) –0.70 (–1.79 to 0.40) –0.07 (–1.15 to 1.02) 0.25
HADS depression,
x (CI)
Baseline 8.19 (7.22 to 9.17) 8.38 (6.95 to 9.81) 8.01 (6.70 to 9.32)
12 weeks 7.89 (6.91 to 8.88) 7.77 (6.27 to 9.26) 8.01 (6.74 to 9.29)
Change score –0.30 (–1.05 to 0.45) –0.61 (–1.51 to 0.29) 0.00 (–1.17 to 1.17) 0.28
EQ-5D VAS,
x (CI)
Baseline 54.00 (48.36 to 59.64) 53.32 (45.42 to 61.23) 54.68 (46.44 to 62.92)
12 weeks 52.81 (45.92 to 59.69) 55.25 (45.87 to 64.63) 50.36 (41.04 to 59.69)
Change score –1.19 (–8.79 to 6.40) 1.93 (–8.58 to 12.44) –4.32 (–14.54 to 5.91) 0.21
SEMCD Scale,
x (CI)
Baseline 5.54 (4.96 to 6.11) 5.50 (4.65 to 6.34) 5.58 (4.79 to 6.37)
12 weeks 5.54 (4.95 to 6.12) 5.65 (4.82 to 6.49) 5.42 (4.61 to 6.23)
Change score 0.00 (–0.50 to 0.50) 0.16 (–0.55 to 0.86) –0.16 (–0.89 to 0.57) 0.38
FAMCARE-P16,
x (CI)
Baseline 45.93 (41.92 to 49.94) 45.59 (39.43 to 51.75) 46.27 (41.05 to 51.50)
12 weeks 44.97 (40.36 to 49.57) 45.82 (39.30 to 52.34) 44.11 (37.83 to 50.39)
Change score –0.96 (–4.85 to 2.93) 0.23 (–5.27 to 5.73) –2.16 (–7.43 to 3.11) 0.37
Secondary caregiver outcomesb
ZBI-12, x (CI) Baseline 18.58 (15.56 to 21.61) 18.47 (14.09 to 22.86) 18.69 (14.95 to 22.44)
12 weeks 18.45 (15.18 to 21.72) 18.62 (13.94 to 23.30) 18.28 (14.24 to 22.32)
Change score –0.13 (–1.70 to 1.43) 0.15 (–1.71 to 2.00) –0.42 (–2.75 to 1.91) 0.58
ZBI positivity,
x (CI)
Baseline 19.02 (17.04 to 21.00) 19.26 (16.49 to 22.04) 18.77 (16.18 to 21.36)
12 weeks 17.95 (15.81 to 20.08) 18.37 (15.37 to 21.38) 17.52 (14.85 to 20.19)
Change score –1.07 (–2.61 to 0.46) –0.89 (–2.66 to 0.87) –1.25 (–3.58 to 1.08) 0.61
FAMCARE 2,
x (CI)
Baseline 52.89 (47.95 to 57.83) 52.94 (46.34 to 59.54) 52.83 (46.40 to 59.26)
12 weeks 49.22 (42.51 to 55.93) 48.98 (41.22 to 56.75) 49.45 (40.61 to 58.30)
Change score –3.67 (–9.96 to 2.63) –3.96 (–11.06 to 3.14) –3.38 (–11.50 to 4.74) 0.87
VAS, visual analogue scale.
a p-value for two-group comparisons using GLMM, adjusting for baseline score and ethnicity with centre modelled as
a random effect.
b 99.55% CIs, Bonferroni correction to control for multiple testing (adjusted alpha = 0.0045, 0.05/11).
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Adverse events and attrition
Attrition was summarised using the MORECare classification of attrition due to death, attrition due to
illness or attrition at random. The levels of attrition up to the primary end point of 12 weeks were
similar in the SIPC group to that of the standard care group (attrition due to death = 5 vs. 3; attrition
due to illness = 1 vs. 1; and attrition at random = 7 vs. 6). Within the attrition at random group,
reasons for withdrawal included no longer wanting to participate, caregiver/family decision to
withdraw and those lost to contact. As presented in Table 11, there were no significant differences in
rates of serious adverse events or survival, up to 12 weeks, between the trial arms.
Health economics
Service use
Service use and associated costs per user for the 12 weeks prior to randomisation and the 12 weeks
post randomisation are presented in Table 12. The number of people using each different category of
service or care and the average costs per user (not per participant in that trial arm) for that category
were counted and calculated. At baseline, 40 and 36 participants had used inpatient care in the
previous 12 weeks in the SIPC and standard care groups, respectively. By 12 weeks, this had fallen
in both groups, to 18 participants in the SIPC group and 25 participants in the standard care group.
Outpatient care use also decreased from baseline to 12 weeks in both groups. Changes in use of
primary care services were not different between the trial arms and the average cost did not change.
The number of patients using palliative care services increased from baseline to 12 weeks in the SIPC
group, whereas there was no change in the standard care group. At 12 weeks, fewer patients in the
SIPC group used inpatient care and more patients used palliative care services than those in the
standard care group. However, a small number of participants in the standard care arm reported
receiving palliative care services, which remained unchanged from baseline to 12 weeks. Informal care
costs (and the amount of care provided by lay carers and family members) remained broadly similar
over the 12 weeks; there was a small reduction in both study arms, with a slightly greater reduction in
the SIPC arm, but CIs were wide.
Costs
To better understand the overall health and social care costs, for each category, we calculated average
costs across all participants. Table 13 shows the average costs of each service for all trial participants,
by trial arm. The average cost of inpatient care at 12 weeks was £899 (95% CI £445 to £1353) in the
SIPC group and £1169 (95% CI £677 to £1662) in the standard care group. The reduction in inpatient
care costs from baseline to 12 weeks was larger in the SIPC group (–£768) than in the standard care
group (–£569). The SIPC arm has lower costs overall, mainly as a result of fewer participants being
cared for within inpatient services. The increase in palliative care costs from baseline to 12 weeks was
more substantial in the SIPC group (from £1 to £68) than in the standard care group (from £14 to £25).
TABLE 11 Between-group comparison of serious adverse events and survival up to 12 weeks
Serious adverse events All SIPC Standard care Significance testing
Deaths, n 8 5 3 χ2 (1, 350) = 0.49; p = 0.49
Hospitalisation, n 25 13 12 χ2 (1, 350) = 0.03; p = 0.86
Emergency attendance, n 7 2 5 χ2 (1, 350) = 1.35; p = 0.25
Survival in weeks
Mean (SD) 11.7 (1.4) 11.6 (1.6) 11.8 (1.2) t (348)= –1.09; p = 0.28
Range 0.1–12 0.6–12 0.1–12
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TABLE 12 Per user care costs at baseline and 12 weeks post randomisation, and changes in health and social care costs by trial arm
Measure Time point
All SIPC Standard care
p-valuean x (95% CI) n x (95% CI) n x (95% CI)
Inpatient care Baseline 76 7840 (6649 to 9032) 40 7336 (5904 to 8768) 36 8401 (6391 to 10,411)
12 weeks 43 7681 (6406 to 8956) 18 7890 (5746 to 10,035) 25 7531 (5839 to 9223)
Outpatient care Baseline 263 140 (123 to 157) 132 146 (120 to 170) 131 134 (112 to 157)
12 weeks 187 157 (126 to 188) 101 148 (108 to 188) 86 168 (118 to 217)
Day or community care Baseline 40 941 (682 to 1199) 22 955 (601 to 1310) 18 923 (504 to 1342)
12 weeks 47 868 (599 to 1138) 24 814 (438 to 1189) 23 925 (508 to 1341)
Home care Baseline 172 150 (114 to 186) 83 170 (102 to 238) 89 132 (100 to 163)
12 weeks 157 142 (104 to 181) 79 144 (80 to 208) 78 140 (95 to 185)
Palliative care Baseline 13 196 (–58 to 449) 5 39 (1 to 76) 8 294 (–142 to 730)
12 weeks 34 436 (283 to 589) 26 415 (253 to 578) 8 503 (32 to 975)
Rehabilitation Baseline 85 999 (276 to 1722) 44 1535 (206 to 2864) 41 424 (–63 to 911)
12 weeks 68 876 (22 to 1730) 35 321 (130 to 512) 33 1465 (–310 to 3239)
Primary care Baseline 184 96 (84 to 108) 94 96 (81 to 112) 90 95 (76 to 114)
12 weeks 144 93 (81 to 105) 69 98 (80 to 116) 75 88 (73 to 103)
Social care Baseline 133 980 (644 to 1317) 60 859 (592 to 1126) 73 1080 (501 to 1660)
12 weeks 125 775 (632 to 918) 60 775 (579 to 971) 65 775 (562 to 988)
Tests and diagnostics Baseline 155 131 (90 to 171) 83 114 (77 to 151) 72 150 (73 to 227)














































































































































































































































































































































TABLE 12 Per user care costs at baseline and 12 weeks post randomisation, and changes in health and social care costs by trial arm (continued )
Measure Time point
All SIPC Standard care
p-valuean x (95% CI) n x (95% CI) n x (95% CI)
Health and social careb Baseline 302 3152 (2552 to 3752) 150 3237 (2357 to 4117) 152 3068 (2241 to 3894)
12 weeks 265 2329 (1817 to 2841) 132 2020 (1451 to 2588) 133 2636 (1781 to 3491)
Informal care Baseline 280 1061 (914 to 1209) 137 938 (735 to 1,140) 143 1180 (966 to 1394)
12 weeks 227 933 (796 to 1069) 108 826 (634 to 1,017) 119 1030 (835 to 1225)
Total carec Baseline 309 4042 (3433 to 4652) 155 3961 (3061 to 4862) 154 4123 (3293 to 4954)
12 weeks 278 2982 (2482 to 3481) 138 2578 (2020 to 3136) 140 3380 (2552 to 4207)
Change in health and social care Observed 257 –828 (–1475 to –180) 126 –1170 (–2035 to –306) 131 –498 (–1466 to 470) 0.17
Change in total care Observed 274 –929 (–1561 to –296) 135 –1185 (–2044 to –326) 139 –680 (–1617 to 257) 0.11
a p-value for two-group comparisons using GLMM, adjusting for baseline values with centre modelled as a random effect.
b Sum of health and social care and informal care.





























TABLE 13 Average care costs per person at baseline and 12 weeks post randomisation, and changes in health and social care costs by trial arm
Measure Time point
All SIPC Standard care
p-valuean x (95% CI) n x (95% CI) n x (95% CI)
Inpatient care Baseline 350 1702 (1278 to 2127) 176 1667 (1111 to 2223) 174 1738 (1090 to 2387)
12 weeks 319 1035 (702 to 1369) 158 899 (445 to 1353) 161 1169 (677 to 1662)
Outpatient care Baseline 350 105 (91 to 120) 176 109 (88 to 131) 174 101 (82 to 120)
12 weeks 319 92 (72 to 112) 158 95 (67 to 123) 161 90 (60 to 119)
Day or community care Baseline 350 108 (65 to 150) 176 119 (57 to 182) 174 95 (38 to 153)
12 weeks 319 128 (77 to 179) 158 124 (53 to 194) 161 132 (57 to 207)
Home care Baseline 350 74 (54 to 93) 176 80 (46 to 114) 174 67 (48 to 86)
12 weeks 319 70 (50 to 90) 158 72 (39 to 106) 161 68 (44 to 92)
Palliative care Baseline 350 7 (–2 to 16) 176 1 (0 to 2) 174 14 (–5 to 32)
12 weeks 319 46 (25 to 68) 158 68 (33 to 103) 161 25 (0 to 50)
Rehabilitation Baseline 350 243 (64 to 421) 176 384 (47 to 721) 174 100 (–14 to 214)
12 weeks 319 187 (4 to 369) 158 71 (25 to 117) 161 300 (–60 to 661)
Primary care Baseline 350 50 (42 to 58) 176 51 (40 to 62) 174 49 (37 to 61)
12 weeks 319 42 (35 to 49) 158 43 (32 to 54) 161 41 (31 to 51)
Social care Baseline 350 373 (236 to 509) 176 293 (185 to 401) 174 453 (200 to 706)
12 weeks 319 304 (234 to 373) 158 294 (200 to 388) 161 313 (210 to 416)
Test and diagnostic Baseline 350 58 (39 to 77) 176 54 (34 to 73) 174 62 (29 to 95)














































































































































































































































































































































TABLE 13 Average care costs per person at baseline and 12 weeks post randomisation, and changes in health and social care costs by trial arm (continued )
Measure Time point
All SIPC Standard care
p-valuean x (95% CI) n x (95% CI) n x (95% CI)
Health and social careb Baseline 350 2720 (2190 to 3249) 176 2759 (1991 to 3527) 174 2680 (1942 to 3417)
12 weeks 319 1935 (1499 to 2370) 158 1687 (1198 to 2176) 161 2177 (1456 to 2899)
Informal care Baseline 350 849 (723 to 975) 176 730 (562 to 898) 174 970 (782 to 1158)
12 weeks 319 664 (556 to 771) 158 564 (421 to 708) 161 761 (601 to 921)
Total carec Baseline 350 3569 (3014 to 4123) 176 3489 (2674 to 4304) 174 3650 (2889 to 4410)
12 weeks 319 2598 (2150 to 3047) 158 2252 (1747 to 2757) 161 2939 (2199 to 3687)
Change in health and social care Imputed 350 –797 (–1424 to –169) 176 –1076 (–1929 to –222) 174 –514 (–1448 to 419) 0.12
Change in total care Imputed 350 –1081 (–1726 to –435) 176 –1350 (–2231 to –470) 174 –808 (–1746 to 131) 0.12
a p-value for two-group comparisons using GLMM, adjusting for baseline values with centre modelled as a random effect.
b Sum of health and social care and informal care.





























Taking the results for all data together, there was a decrease in overall health and social care costs
(inpatient, community, outpatient, home, palliative, rehabilitation, primary, social care, and tests and
diagnostics) from baseline to 12 weeks of –£1076 in the SIPC group and –£514 in the standard care
group. The resulting difference across study arms was –£562. This difference is mainly driven by the
differences in inpatient care use. Informal care costs were similar between study arms. Correspondingly,
total care costs (health and social care plus informal care) also decreased from baseline to 12 weeks
by –£1350 in the SIPC group and –£808 in the standard care group, with a resulting difference of
–£542 between groups. Overall, it was less expensive to provide care for the SIPC group than to
provide standard care. The CIs are wide and individual costs varied greatly. No significant between-
group differences were observed for either the change in health and social care costs (p = 0.12) or
the change in total care costs (p = 0.12).
Outcomes
Two outcome measures were used in the economic evaluation: IPOS Neuro-S8 (as presented
previously) and EQ-5D index score (or QALY). The mean EQ-5D index score at baseline was 0.27
(95% CI 0.22 to 0.32) in the SIPC group and 0.26 (95% CI 0.21 to 0.31) in the standard care group. At
12 weeks, the mean scores were 0.26 (95% CI 0.21 to 0.32) and 0.23 (95% CI 0.18 to 0.28), respectively.
The respective change scores were –0.01 (95% CI –0.05 to 0.03) and –0.03 (95% CI –0.07 to 0.00),
indicating that deterioration in quality of life was greater in the standard care group than in the SIPC
group. The difference in QALY measured by EQ-5D was not significant between the two groups
(p = 0.26).
Cost-effectiveness analysis
Incremental cost-effectiveness ratios were calculated for those for whom both cost data and the
outcome measures were available. ICERs were calculated as the ratio of differences in health and
social care cost and outcomes (rescaled IPOS Neuro-S8 and EQ-5D index score). Using health and
social care cost, in other words, when taking an NHS perspective, the change in cost in the SIPC
group between baseline and 12 weeks was –£1076, compared with –£514 in the standard care group,
leading to a –£562 between-group difference. For the rescaled IPOS Neuro-S8, the change scores
were 0.75 and 0.38, respectively, resulting in a between-group difference of 0.37. For the EQ-5D index
score (QALY), as presented above, the respective change scores were –0.01 and –0.03, with a resulting
between-group difference of 0.02.
As shown in Table 14, the ICER for IPOS Neuro-S8 was –£1519. As the IPOS Neuro-S8 was rescaled,
higher scores correspond to lower symptom burden. The ICER suggests that an improvement of 1 unit
in IPOS Neuro-S8 is associated with an on average per patient decrease in health and social care costs
of –£1519 compared with standard care. The ICER for EQ-5D index score was –£23,545. With higher
scores indicating better quality of life, an improvement of 1 unit (QALY) was less costly in the SIPC
group than in the standard care group by £23,545.
TABLE 14 Incremental cost-effectiveness ratio of health and social care cost and EQ-5D and IPOS Neuro-S8
Changes in outcomes and cost between baseline and















Imputed data (n = 350) –0.01 –0.03 0.75 0.38 –1076 –514 –23,545 –1519
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The ICER for health and social care cost and EQ-5D index score was well below our pre-determined
threshold of £20,000. Sensitivity analyses conducted in line with the main effectiveness analyses
produced consistent results.
Bootstrapping was used to obtain 1000 replications of the ICERs. As presented in Figure 2, when
bootstrapped differences in EQ-5D index score and health and social care costs were plotted on cost-
effectiveness planes, 74% of replications were found in the fourth quadrant and with rescaled IPOS
Neuro-S8 as the outcome measure, 84% of replications were in the fourth quadrant (which represents
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FIGURE 2 Cost-effectiveness planes of outcome measures (a) EQ-5D index score (QALY); and (b) rescaled IPOS
Neuro-S8, and health and social care cost.
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Qualitative findings
Patient and caregiver participants
Twenty-six interviews were carried out with 26 patients and 16 caregivers from three trial centres
(London, Brighton and Ashford). Interviews lasted a median of 43 minutes (range 20–93 minutes).
Participant demographics are detailed in Table 15. The majority of the interviews were conducted with
patients with MS (69%). Most had lived with their condition for a considerable time (mean 13.7 years
since diagnosis, SD 10.5 years). Caregivers tended to be younger than the patients (caregivers’ mean
age 58.9 years; patients’ mean age 63.5 years), were mainly women (62.5%) and were a spouse or
partner (68.8%). Participant characteristics for caregivers who were interviewed are presented in full in
Appendix 4.
Health-care participants
Focus groups were conducted with health-care staff involved in delivering SIPC in six of the study
centres. Groups comprised six palliative care teams and one neurology team. Additionally, three
TABLE 15 Patient demographics for qualitative interview participants
Variable Value Interviewed patients (N= 26)
Age (years), mean (SD) 63.5 (13.5)
Gender, n (%) Man 14 (53.8)
Woman 12 (46.2)




Mean (SD) 13.7 (10.5)
Range 0–38
Comorbidities, n (%) No 5 (19.2)
Yes 21 (80.8)
Patient capacity, n (%) Consent 24 (92.3)
Personal consultee assent 2 (7.7)
Baseline IPOS Neuro-S8
Mean (SD) 8.2 (4.1)
Range 2–17
Living status, n (%) Alone 6 (23.1)
With spouse/partner and/or children 16 (61.5)
With friend(s)/with others 4 (15.4)
Ethnicity, n (%) White 23 (88.5)
Other ethnic group 3 (11.5)
Employment, n (%) No 25 (96.2)
Yes 1 (3.8)
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individual interviews were conducted with members of neurology teams. A total of 43 health-care
providers participated. Palliative care team members included consultants in palliative medicine,
clinical nurse specialists, occupational therapists, clinical service managers, a chaplain and an
administrator. Neurology team members included consultants in neurology and disease-specific
clinical nurse specialists.
Overarching themes on the value and impact of short-term integrated palliative care
The value and impact of SIPC, and linkage with key components for delivery, is encompassed in
three overarching themes: (1) adapting to losses and building resilience, (2) attending to function,
deficits and maintaining stability and (3) enabling caregivers to care. Overall, the themes illustrate
the complexity of living with a progressive neurological condition, the daily work of patients and
caregivers to accommodate ongoing losses and to adapt to maintain stability in function, and the
optimal management of disease and symptoms. The strategies used were typically honed over many
years. There were rarely ‘quick fixes’. What was required was attention to the multiple domains of
health and interaction between domains, person-centred care to understand priorities and how to
enable pursuit, and integrated working across health care to optimise continuity of care and treatment
and minimise duplication.
Outcomes were often subtle, the ‘softer things’ of skilled supporting to enable patients and caregivers
to manage daily life and live life as well as possible. Skilled support involved skilled listening, appreciation
and understanding of the condition, and availability of accessible services responsive to deterioration,
to minimise a domino effect of decline, and reviewing care and treatment, to maintain stability. Optimal
management required attention to psychological, social and physical concerns: not an either or. The
role of the MDT was essential to attend to the multiple domains of health. Interventions were required
to attend to points when the patient’s health was unstable (when care and treatment were no longer
keeping up with disease progression and symptoms and concerns) or stable (to enable the patient and
the caregiver to maintain stability by supporting adaptation, problem-solving and resilience).
Each of the three themes are explored in relation to respective subcategories, with exploration of
divergent cases. The intention is to inform theoretical understanding on a model of SIPC within
the wider context of health and social care systems of delivery. The overview of the analytical
framework on the value and impact of SIPC and linkages with key components for delivery are
presented in Appendix 5. The table in Appendix 5 defines respective themes and subcategories and
details illustrative quotations.
Theme 1: adapting to losses and building resilience
Patients and caregivers described living with a LTNC as ‘always troublesome’. Adapting to losses
and building resilience were key strategies to adjust to increasing disability and declining function.
Psychosocial interventions were valued to support resilience and adaptation, and counter feelings
of loneliness and isolation, often combined with little understanding of their progressive condition.
The theme is formed by two subcategories: (1) care beyond medicines, exploring psychosocial
interventions; and (2) asked about everything, focusing on planning future care.
Care beyond medicines
Patient and caregiver concerns comprised multiple interacting components, linkages across health
domains, and the ongoing work of adapting to living with a progressive condition and a ‘knowing
outcome’ that leads to end of life. Interventions needed to encompass the breadth of actual or
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potential contributing factors to decline in emotional well-being. Optimal management of physical
symptoms, using both pharmacological and non-pharmacological approaches, was often seen as the
route to improving emotional well-being:
Well it’s [emotional feelings] sort of linked to my physical feelings really so I didn’t feel like I was ever
gonna improve but I have begun to improve. I’m feeling a bit ill and fluey and that sort of winter feeling
at the moment, but the massage [sessions from palliative care practitioner] was the start I think of me
feeling better, and getting more sleep and feeling more generally well in myself. So it’s a subtle change in
some ways but in some ways it’s quite a large thing cos just going to bed was a nightmare, I just couldn’t
sleep at all and it was making me more tired and it seemed to make the symptoms worse in the morning
and during the day and so I think it’s a good thing that I can actually go to bed and just sleep again since
being on this course.
P05182-M
Psychosocial interventions encompassed person-centred care with comprehensive assessment,
including social, emotional and physical health, not limited to the disease, and drawing on the skills
of the MDT for delivery. Importantly, interventions also included practical support, advocating on
patients’ behalf by following up referrals to services or for equipment, financial support reviewing
and advocating (e.g. social care benefits), and non-pharmacological interventions of massage and
acupuncture, attending to physical and emotional well-being. However, respite care was an area of
frustration, seen as a vital resource but with varying provision and quality.
Person-centred care was key to optimal management of psychosocial concerns. The complexity of
presentation required careful assessment and understanding of patient and caregiver priorities for care
and treatment. Attention needed to focus on empowering patients and caregivers by understanding
perspectives and priorities to enable shared decisions about care and treatment. When present, this
appeared to build resilience and enable management of conditions, and, when absent, a sense of
frustration and anger at the loss of personhood:
I don’t necessarily errm have a huge amount of confidence in them [antidepressants] and actually
[palliative care nurse, PC1] agreed that because of the errm TN [trigeminal neuralgia] particularly, errm
and because of the carbamazepine that she would be on, increased doses she probably said that actually
it probably wouldn’t be recommended in your mum’s case and the GP [general practitioner] also agreed.
So errm yeah we discussed it, but we kind of decided that it probably wouldn’t be best for mum . . . But
again, it was nice to have someone actually say ‘Actually you’re probably right’. Errm because you kind of
don’t get a handbook in going through things like this and you just have to really, it’s a bit of a minefield
and you have to kind of make your way through it yourself. And there have been occasions when I’ve
thought ‘Oh my God, should she be on them?’ And then we’ll try something and there’ll be nothing.
C01280-F
. . . people are only interested in your medical symptoms and not about your feelings or about your
general condition. People are just interested in your drugs and general welfare. So it’s difficult to say.
I think that people really didn’t care about you as a person just as a patient, shall we say, if you know
that difference. That’s the best way I could say it I think. They didn’t seem to take much interest in what
you thought, just whether you could do this or do that.
P06339-F
Assessment and management of psychosocial concerns required an accessible service, ‘it takes away
worry knowing I can call’ (C05275-F), and a high level of skill and time to provide the level of support
required to explore fears, and the ongoing process of adaptation and resilience, ‘We don’t, we don’t let
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ourselves get sad and unhappy cos you’ve gotta deal with that . . .’ (C01291-F). For both patients and
caregivers, the act of asking, acknowledging and problem-solving was welcomed and valued:
. . . it sort of like makes you feel better if you know what I mean you know when you speak to her
[palliative care nurse] and that, you know, you, sort of the help you get and that from them, you know,
brilliant really.
C05275-F
However, with increasing complexity of presentation and management, the short-term intervention
seemed to limit opportunity to establish rapport and trust, and review and to evaluate the ongoing
process of managing psychosocial concerns, such as depression, and reconciling losses and fears about
the future:
No, it’s not something we talked about [grieving for my body and the life I had before MS]. I did tell her
[the palliative care nurse] that I feel very lonely at times but we didn’t talk about counsellors [that I saw
many years ago and that was helpful] or anything like that . . . maybe that is something I should have
asked for.
P01348-F
She convinced me to go back on some medications [antidepressants] which I said no to, so she talked and
finally persuaded me to go back on those, which I’ve been on quite some time ago then I stopped and so
on . . . I had them but was not eager to take them, and after [palliative care nurse, PC1N] handled it
differently . . . yeah it made me feel better [after taking them again], but it’s not enough . . . and for this
reason, I reject all medications because they’re not intended to make a big help, they just maintain certain
level of healthiness, you know.
P01325-M
Asked about everything
Difficult conversations about ‘emotional things’ to adapt to a progressive condition and end of life
required trust and rapport. The short-term nature of the intervention confined the time to build this.
Sensitive topics were introduced by palliative care practitioners asking about thoughts on the future,
but patients and caregivers seemed uncertain about engaging in such conversations. Planning future
care for the end of life was marked by uncertainty in ‘not knowing what’s going to take hold’ when
living with a LTNC, and fear of increasing disability and loss of capacity. Engagement ranged from
‘not at all’ to ‘I’ve been writing stuff down for years’, as demonstrated in Figure 3.
For both patients and caregivers, these conversations were difficult, and when broached by palliative
care team members there was a tendency to ‘skirt-around’ talking about the future. Although
individuals could see the practical benefits of planning care for the future, fear and uncertainty seemed
Not at all
It’s too soon
Got no control over that [when I die]
I just live each day
Don’t know what’s going to take hold
We don’t feel we need to decide
I’ve been writing stuff down for years
DNACPR and preferences documented with solicitor
Discussed with family ‘Just let me go’
Bad enough physical side of disability, don’t want to end up unable to talk
If disease progressed to the most awful stages you can forget it [don’t
resuscitate me]
FIGURE 3 Engagement with planning future care for the end of life. DNACPR, do not attempt cardiopulmonary
resuscitation.
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to inhibit pursuit of such conversations. It was an area that required time for building trust and pacing
to the individual:
. . . and I dread the thought of that [what happened to my mother with dementia] happening to me. Being
spoken to like a small boy, I, that would just finish me off. I mean I, my mother had her own house. She
had dementia, they spoke to her like a little girl, and I thought ‘you’ll not do that to me, speak to me like
a child’ because I’m the one that owns this house, I pay the bills and just because I’m not well, whatever
which shape or form, I won’t have that. I could be quite a difficult patient I feel as I get older . . . I haven’t
got a family so I care for myself and when I can’t do, then maybe I’ll have to think again. But at the
moment I don’t want to [think about wishes for care and treatment in the future].
P05258-M
Planning care seemed to focus on the present of managing each day, or confined to practical issues of
setting up a power of attorney or making a funeral plan. Advance care planning discussions appeared
to be the beginning of a conversation: checking in about what the person thought and offering contact
with the palliative care team to discuss in the future:
P05345-M: Yeah I think you have to, everybody with any kind of medical condition you have to talk
about things like that [wishes for care and treatment in the future].
C05345-M: Yeah that wasn’t, we hadn’t really thought about things like that before.
P05345-M: Yeah that was beneficial, to think about it . . .
C05345-M: Open our minds a bit I suppose.
P05345-M: . . . of what might happen in the future.
Theme 2: attending to function, deficits and maintaining stability
It was important for patients and caregivers for SIPC to attend to physical needs. This required services
to encompass the duality of supporting function to maintain independence, however small, and
optimal management of deficits of unstable symptoms amenable to changes to reduce distress.
Behind this duality was a background of maintaining stability, requiring daily adaptation and resilience
by patients and caregivers to manage a progressive condition with ongoing multiple losses across
domains of health. These areas formed two subcategories: (1) little things make a big difference, and
(2) maintaining stability.
Little things make a big difference
Optimal management of physical needs required a focus on reducing the distress of unstable
symptoms (breathlessness, pain, including spasm, excessive saliva causing dribbling) and on maintaining
function and independence. Unstable symptoms ranged from discrete areas to multicomponent across
health domains. Interventions enabled stabilising of symptoms, with seemingly small changes in
medication making a ‘big difference’ to how symptoms affected well-being. What was important was
the timing to intervene early at points of deterioration to prevent a ‘domino effect’ of symptoms:
I mean her mobility, her, her dementia [from primary progressive MS] is all stuff that has kind of
deteriorated obviously as we’ve been going along unfortunately errm she’s had issues with her swallowing
errm we think there might be a little bit of dysphasia there, that’s actually as we speak being investigated
so we’re waiting for a referral for, from speech therapy, errm because she is, she’s losing a lot of weight
errm and her appetite is just most of the time really non-existent . . . You can’t do anything when
someone’s in pain unfortunately so I think that was, she [palliative care nurse] probably came in at the
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right time that it you know, it, it couldn’t have been better timing really for us errm it just so happened
that at that point in time she was really going through a really tough time with the TN [trigeminal
neuralgia]. So, but there’s always gonna be challenges, I don’t think there’s, you know, gonna be a time
where everything is necessarily errm you know, staying on a same level, it’s always gonna be progressive
because unfortunately that’s the nature of primary progressive MS.
C01280-F
[My husband] was obviously getting embarrassed [dribbling saliva], you know, family came or we wanted,
he wouldn’t go out for a meal or anything like that then. No, and again it’s something again, he told the
others, and nothing was really, something was suggested but nothing followed through which is this,
wasn’t it, the drops . . . But she [palliative care nurse], she done it, she did, you know . . . It’s not, it’s I
would say it’s a good 50% better than what it was, isn’t it? . . . He was [also] getting jumpy legs, or what
he calls irritable legs and they would jump, he’d be in bed and he’d twitch, keep twitching wouldn’t you?
We know it’s part of Parkinson’s but it was, he wasn’t getting any sleep, but at least you get some sleep
now don’t you? . . . It’s still there, because you won’t sort of clear it up but it’s, well a good 75% better
[following SIPC medication change]. [C01335-F]. 90% [better]. [P01335-M].
Caregiver and patient dyad, C01335-F and P01335-M
Divergent cases illustrated the complexity of symptom management when living with multiple symptoms.
Many patients had ‘tried many things’ over time, with, at times, optimal care and treatment having little
impact on symptom severity. What mattered to patients and caregivers was ‘to know people are available
and willing to try and improve symptom management’. Optimal management required interdisciplinary
working across MDTs, and integrated working with main providers of care to maintain continuity of care
and treatment. Disrupting continuity of care and treatment, with perceived no benefit or negative effect,
increased distress:
My life hasn’t changed [from seeing palliative care nurse] except maybe in the short term, for a bit of
aggravation and trouble that she caused me, because I’ve had to put everything back the way it was and
I won’t complain about the tiredness again. Because if it’s, if it is the tramadol [analgesia] that caused the
tiredness then so be it, I will accept it. But I can’t, as I said to you, I don’t want to be in pain.
P05258-M
Maintaining function through supporting adaptation and problem-solving (e.g. continence, mobility, falls
prevention, eating and drinking) was highly valued and felt to support independence. Key components
were the involvement of the MDT, notably occupational therapy (OT) to support function, and physiotherapy
and complementary therapies to provide non-pharmacological interventions to manage symptoms such
as pain, breathlessness and poor sleep. However, when function was seemingly poorly attended to, this
was an area of frustration for patients and caregivers. This was often compounded by their long experience
in health and social care of long waiting times for assessments, loss of neurological physiotherapy services
in the local community, difficulty accessing palliative care services if this had required travelling to day
services, or ‘nothing happened’ following referral to community OT or physiotherapy by the palliative
care team:
Simple things. And that’s what I think they [the palliative care team] need to educate their self about if
they want to help . . . No, with palliative care, that word is to help you, comfortable . . . live life better, a
little bit better . . . For her [palliative care nurse] knowledge, we’re not knowledgeable people . . . But she’s
got the, the, errrm probably the experience to have walked in anywhere and said to [patient’s name] well
you know, he’s sitting there in a chair and he’s like that so what would you think? . . . He hasn’t got no
support in his spine, which is, giving him drugs for his pain, but they’re not preventing it . . . See that could
have been prevented a long time ago but because of the system, they [palliative care] don’t seem to assess
it . . . [he’s] got progressive and, all this, falling over.
C01286-F (caregiver and patient dyad, C01286-F and P01286-M)
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Maintaining stability
Although they are living with extensive losses and deficits, patients considered themselves ‘stable’
with no concerns, but worked every day to maintain that stability. SIPC was about skilled support to
increase awareness and understanding of disease management, symptoms and concerns, and being
available for individuals to call for advice and support if things changed. This was a seemingly subtle
soft outcome. Some patients and caregivers considered no or little impact on well-being from the
involvement of palliative care, with ‘troubles’ the same as always, which they worked continuously
to live with and adjust to:
Well the thing is, I don’t, I don’t, I don’t feel like I’m trouble, I’ve got any troubles. I, I obviously I’ve got
short memory and . . .
P01286-M
He’s [my husband] got adjusted to his disability . . . but before she came, it was no different to what it was
all the time . . . by [Palliative care practitioner, PC1] coming it wasn’t a miracle cure . . . it wasn’t, suddenly
she turned up and it . . . all my worries are gonna go and errr all my troubles and worries are just
gonna disappear.
C01286-F
Theme 3: enabling caregivers to care
Acknowledging and valuing the work and care given by caregivers meant a lot, with appreciation of
someone to talk to and to be reassured of doing a good job. When not acknowledged, this was a
source of frustration for caregivers, who wanted to be asked ‘How are you?’, and when they were
asked this they were surprised, as there was a tendency for care and attention to focus on the patient.
Caregivers expressed feelings of having had to ‘fight for everything’ and to become experts in the
person’s care. The ability to call the palliative care team for advice, particularly out of hours, as well
as opportunities to talk through care and treatment, were important to empower decision-making:
Errm you’ve either got to be a strong-minded person or just plod along and put up with it which I have.
I’ve had a lot of stress, fighting the system for everything. As far as she [the palliative care nurse] was
concerned, she was here mostly for [my husband] and not for the person who’s here 24 hours a day, or
not 24 hours a day but lives here as his wife and carer. Errm she didn’t say to me ‘Is there anything you
think that could be done to help you with caring for your husband?’.
C01286-F
Caregivers indicated a tendency not to ask for help, putting their loved ones before themselves and not
allowing themselves to be vulnerable or ‘selfish’ in putting their own needs first. Not acknowledging need
for help was complex, linked to fear that asking may trigger thinking that they are unable to cope, ‘Better
to keep coping rather than risk downward spiral of thinking I can’t manage’. Without support there was a
risk of caregivers eventually breaking psychologically and physically from the strain and worry, particularly
when not recognising the limits of their resources and the importance of caring for themselves. This type
of ongoing work required trust and rapport for the caregiver, to gradually understand the increasing
demands placed on them and how to best manage these. Supporting caregivers who had complex
concerns required the continuity of care provided by neurology services, particularly community-based
nurse specialists. Working with the palliative care team provided the ‘final prompt or prod’ to
enable change:
Well not so much someone to talk to but [Parkinson Clinical Nurse Specialist, NN1], she’s been absolutely
brilliant and errm her sort of enthusiasm, I mean she’s been talking to me about giving up work for a long
time and kept on saying stop being so stubborn, you know, why can’t you just listen or why can’t you just
you know give up and look after [your wife] full time, have quality of life, and I, it came to the stage
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where it was really difficult in that it was now, it has to happen now and you just sort of errm put it
aside, put it aside until we moved, errm where it just suddenly hit me, you know just near the kitchen I
thought ‘no I can’t carry on’. I phoned my boss, I said ‘look I’m having a bit of a breakdown here’ . . . he
[my boss] said ‘well we’ve actually been waiting, wondering how long you’re going to last for, we’ve been
waiting for your breakdown’. I thought ‘thanks’ you know [laughs] but that was done, they were brilliant
you know up until I finally left.
C01007-M
Change process and delivery in practice
The overarching themes provided understanding on the outcomes that are important for patients and
caregivers, and linkages with key components of models of care to delivery. Important outcomes from
SIPC centred on three main areas:
1. Psychosocial well-being of adapting and having the resilience required to live with, and
accommodate, multiple ongoing losses leading eventually to end of life.
2. Physical well-being of supporting function to promote independence, optimal management of
physical symptoms, with emphasis on person-centred care, pharmacological and non-pharmacological
interventions, and accessible services responsive to points of deterioration to minimise a domino
effect of decline.
3. Empowering caregivers to care through recognition and valuing of work, shared decision-making
and accessible services for advice and support, including practical support.
Complexity was an over-riding feature across the narrative data, surrounding all aspects of care:
management of progressive disease; symptoms that appeared refractory, with little response
to pharmacological interventions; maintaining independence with increasing disability; adapting
to a multitude of losses leading eventually to end of life, with huge uncertainty as to when; and
empowering caregivers to continue caring over many years, with increasing demands and losses.
Linkage with the outcomes important for patients and caregivers, their experiences of receiving SIPC
and the processes of delivery described by practitioners’ informed understanding of the overarching
components of a service delivery model for integrated palliative and neurological care. These
components include:
l Comprehensive assessment, encompassing health domains and the priorities for both patients and
their caregivers.
l Person-centred, holistic care, focusing on the person and not the disease alone.
l MDT working, to provide the expertise for attending to function and deficits of symptoms and
concerns across health domains.
l Integrated working between health-care services, to ensure continuity of care between palliative
care and neurological services, and with community and primary care services.
l Integrated working fostered through reciprocal learning and training between specialties, in order
to enhance the provision of palliative care approaches in neurological services and, conversely,
expertise in management of advanced neurological disease in palliative care, with joint case review
of individuals with complex symptoms and concerns.
Intervention fidelity
Of the 176 patients allocated to receive the SIPC, 173 patients received the intervention. Three
patients did not receive the intervention, as two patients withdrew from the trial and one patient could
not be contacted by the respective palliative care team following referral. Of the 173 patients who
received the intervention, all had an initial face-to-face visit for a comprehensive palliative care
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assessment. Following this, 152 patients had a second key worker contact (100 via face-to-face meeting
and 52 via telephone), and 153 patients had a third key worker contact (91 via face-to-face meeting
and 37 via telephone; for 48 patients the type of contact was not recorded). The intervention manual
described the core elements to be covered when assessing patients as part of the SIPC, as well as the
minimum standards for capturing and reporting delivery of the SIPC intervention. The completion rates
of key pro forma documents and core intervention elements are presented in Table 16.
TABLE 16 Intervention data
Variable Value SIPC arm
N 173
Number of key contacts received, n (%) 3 126 (72.8)
2 27 (15.6)
1 20 (11.6)
Duration of first visits in minutes
Mean (SD) 130.9 (75.3)
Range 40–410
Duration of intervention in weeks
Mean (SD) 7.95 (5.06)
Range 0–32
Completion of IPOS Neuro, n (%) 168 (97.1)
Baseline AKPS recorded, n (%) 124 (71.7)
Baseline phase of illness recorded, n (%) 152 (87.9)
Advance care planning discussed, n (%) Yes 122 (70.5)
No 25 (14.5)
Not appropriate/patient declined 26 (15.0)
Discussion in a MDT review, n (%) 164 (94.8)
Compliance, n (%) Complier 120 (69.4)
Partial complier 34 (19.7)
Overuse 1 (0.6)
Dropout 4 (2.3)
Not recorded 14 (8.1)
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Chapter 5 Discussion and conclusions
Key findings
To the best of our knowledge, this is the largest palliative care trial in people with LTNCs.87 We found
that none of the evaluated primary or secondary outcomes were significantly different between those
in the SIPC group and those in the standard care group. However, safety outcomes, including deaths,
survival and hospitalisations, were similar between the two groups, as were rates of withdrawals.
The health economics data showed that care costs fell in both groups between baseline and 12 weeks,
with no statistically significant differences between groups. However, ICERs for EQ-5D index score
and (rescaled to match direction of EQ-5D) IPOS Neuro-S8 were –£23,545 and –£1519, respectively,
considerably better than our threshold for cost-effectiveness. The bootstrapped point estimates in the
cost-effectiveness analysis favoured SIPC, indicating a larger reduction in symptoms on IPOS Neuro-S8
or improvement in EQ-5D along with lower cost. Patients receiving SIPC did show a statistically significant
improvement on the primary outcome of eight key physical symptoms (IPOS Neuro-S8) and the secondary
outcome of 24 physical symptoms (IPOS Neuro-S24) from baseline to 12 weeks after randomisation. A
similar improvement was not seen in the control group. Other than the level of care satisfaction (as measured
by FAMCARE-P16), which became worse in the standard care group, there were no statistically significant
changes in other patient or caregiver outcomes, for example quality of life, anxiety and distress, caregiver
burden and positivity, over 12 weeks, in either group. The qualitative data illustrated the complexity of
living with LTNCs for both patients and caregivers, and the value that participants placed on the holistic
and timely assessment received through SIPC, with attention and assistance given to psychological,
social and physiological concerns. Many symptoms were seen as intractable. The qualitative, mapping
and survey data all demonstrate the need and opportunities for increased collaboration and integration
between neurology and palliative care services, and the challenges resulting from variation across
centres and diseases.
Comparison with literature
Trials evaluating the effectiveness of palliative care for LTNCs are rare, and the existing evidence comes
from a small number of feasibility/pilot studies. In comparison, our trial is large and both multicentre
and multicondition. The overall pattern of results we see is similar to that of the previous Phase II trial
of an early palliative care intervention in people with advanced MS.24 However, in that trial, at 12 weeks,
there was a significant difference in the change score of pain, as well as a significant improvement on
caregiver burden, in the early palliative care group compared with the usual care group. In contrast,
we have not investigated symptoms individually and we did not observe any improvement on caregiver
burden. The latter may not be surprising, as a recent systematic review and meta-analysis highlighted
that findings on caregiver burden in palliative care interventions are conflicting.88 Our qualitative
findings iterate this, illuminating understanding on the complexity of caregivers’ sense of legitimacy
to receive support and the priority they placed on this. In another Phase II trial26 with 78 MS patients
and their caregivers, a 6-month home-based palliative care service was found to significantly reduce
symptom burden as compared with usual care (p = 0.047), with a stronger effect at 6 months (effect
size = 0.32) than at 3 months (effect size = 0.2).26 The authors also observed no difference in other
outcomes, such as quality of life or caregiver burden. A 4-month home-based specialist palliative care
service for 50 patients with advanced neurodegenerative disorders (MND, MS, IPD, MSA and PSP)
found a significant improvement in quality of life and physical symptoms (pain, breathlessness, sleep
disturbance and bowel symptoms) across the conditions, but, again, no effect was seen for caregiver
burden.25 In contrast with our trial, that trial did not include patients without capacity. Of note, none of
the abovementioned trials reported data on intervention fidelity, which is a key factor when evaluating
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complex interventions. Indeed, implementation fidelity in randomised controlled trials of palliative care
for complex interventions is under-recognised and under-reported.89 In contrast to our trial and the
reported trials in neurological condition, studies testing the effectiveness of palliative care interventions
for advanced cancer have shown benefit to multidimensional quality-of-life outcomes and survival,
but less so for physical symptoms.36,90,91 Although the prognosis and trajectories of LTNCs are vastly
different from cancer and even vary for each type of LTNC. In a trial92 evaluating palliative care for
heart failure patients, an improvement on anxiety and depression outcomes, as measured by the HADS,
was also reported.
Interpretation
In this trial, we did not detect a difference between trial arms in the primary outcome, although
we note that, compared with baseline, the scores on the primary outcome improved in both arms,
significantly in the SIPC group and not significantly in the control group. The secondary outcome,
IPOS Neuro-S24, followed this pattern, and the significant reduction in patient satisfaction seen in
the standard care group further supports the trial findings in favour of SIPC. Compared with baseline,
health and social care costs, including inpatient care, community care, outpatient care and home care,
were reduced in both arms at 12 weeks. Although there was no significant difference between groups,
this reduction in costs was larger in the SIPC group. The ICER suggests that, compared with SIPC, the
control arm has a 1 point deterioration in utility at an additional cost of around £1000 per patient. The
ICERs for SIPC are well within the usual thresholds for decision-making in the NHS and recommended
by the National Institute for Health and Care Excellence (e.g. £20,000 or £50,000, as often used in
end-of-life care therapies), making SIPC acceptable as a cost-effective intervention. No harms were
identified and, in general, patients and clinicians welcomed the intervention. In addition, crucially, there
were no increased costs to informal carers and, if anything, their costs may have been slightly lower in
the intervention group.
To base the decision of effectiveness on the statistical significance is a long-recognised misuse of the
p-value. The American Statistical Association released a policy statement in 2016 specifically targeting
this issue.93 A comment paper published in Nature earlier this year updated this concern regarding
pervasive categorisation on the basis of the p-values.94 However, through the mapping, survey and
qualitative components, we also observed variations in integrated working and delivery of care, and
more work is needed to understand the best ways to provide palliative care to this group and how to
improve standard care, which varies considerably.
There may be several possible explanations for the non-significant results. The first relates to the
outcome measures. The primary outcome measure of eight key symptoms (IPOS Neuro-S8) was selected
based on the five symptoms that were most responsive to a palliative care intervention in our Phase II
trial and symptom profile data from a longitudinal observational study of late-stage Parkinsonism
syndromes.27,40 In a preliminary psychometric evaluation, the measure exhibited promising psychometric
properties.68 In this trial, some items of the IPOS Neuro-S8, as well as the IPOS Neuro-S24, showed
strong floor effects at baseline, indicating that some further refinement of the outcome measures,
particularly for a more heterogeneous trial setting like the present one, may be necessary. In our data,
the IPOS Neuro-S8, which measured participants’ psychological and spiritual well-being, information
needs and practical issues, rather than their symptoms, appears to detect more changes.
The other key question is the match between the patient needs and the interventions offered by the
services. Palliative care was first developed mainly for patients with cancer, although it should be
noted that early studies of need and problems identified concerns for people with many different
diseases, including neurological conditions.95–97 It may be that palliative care has not sufficiently
adapted and developed symptom and other treatments as yet for patients with complex LTNCs.
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Much research and therapeutic developments in palliative care have focused on cancer pain and other
cancer symptoms, rather than on the most prevalent symptoms in this population. These include chronic
pain and spasms found in neurological conditions, fatigue, weakness, difficulty sleeping, breathlessness
and problems with mobility.69 These are continuing serious concerns for these patients and their families,
and should be the topic of future research. Such research could benefit care widely, and the therapies
discovered could be applied by those with neurology and rehabilitation backgrounds. Furthermore, the
models of palliative care operation also derived from cancer, and many staff working in palliative care
have a cancer training and not a neurological training. Therefore, the models and approaches offered
by the services may not have been optimal. It may also be that better targeting of the population likely
to benefit from integrated palliative care is needed. Better working and integration between palliative
care and neurology is needed to further improve the models of care for people seriously affected by
neurological conditions. Such an approach needs to rise beyond specialist-defined boundaries and focus
on the best ways of meeting the needs of patients and those important to them.
Additionally, as we used a trial design randomising at the individual level, there may have been some
contamination, whereby participants in the standard care group received some components of the SIPC
intervention. Indeed, this appears to have been the case, because our economic data found that some
people in the standard care arm reported receiving palliative care by 12 weeks, when according to our
design they should not have. Referrals to the palliative care teams for the intervention were carefully
monitored to avoid contamination, but it seems that this did not fully work. Participation in the trial
itself may function as an intervention on some level. This contamination may have occurred through
the research contacts, when participants were visited in their homes by friendly, caring researchers
(often research nurses), who gave them the time to air their concerns and feel listened to. Indeed, our
qualitative findings demonstrate that this was a valued aspect of the holistic assessment received as
part of the intervention and may have been mistaken for palliative care in the standard care arm. As
such, receiving this to some level through the research contacts probably had benefits for those in the
standard care group. In both groups, we saw a reduction in the burden of symptoms, though to a lesser
degree in the standard care group; therefore, although the mean change score in the SIPC group for
the primary outcome was statistically different from zero, this potential contamination may have
further reduced the effect size.
Finally, the SIPC may not have had enough time for the intervention teams to build sufficient rapport
with patients and caregivers to address some of the more complex issues, such as advance care
planning, supporting caregivers and optimal management of refractory symptoms. Some of the needs
identified could be addressed only by referring or signposting to other services (e.g. social services for
review of benefits). Therefore, SIPC often had to rely on the actions of other services that it referred
to or that were catalysed by SIPC. The time scale of 12 weeks may not have been sufficient to ensure
that SIPC could directly act on, or follow up on, its recommendations. It may also be that for some
of the longer-term, more intractable, difficulties that it took longer than 12 weeks to see an effect,
especially of referrals to other services. We were able to collect longer-term follow-up data, and these
will be analysed in future research. Ideally, population-based routine data could be used to augment
this analysis. Nevertheless, the few other trials assessing palliative care interventions in this population
had similar findings despite varying lengths of intervention (up to 6 months).24–26
Strengths and limitations
There are several strengths to this study. To the best of our knowledge, this is the largest palliative
care trial in a non-cancer population and also the first to include more than one common LTNC.
We included patients with cognitive decline who lacked capacity, which is common in neurological
conditions, and recruited their caregivers as the proxy to provide data to inform the imputation
process. We recruited a large number (n = 229) of caregivers of patients with advanced LTNCs and
collected a range of caregiving outcomes, including quality of life, caregiver burden and positivity.
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The randomisation process appears to be successful. The only imbalanced variable at baseline was
ethnicity, with slightly more non-white patients in the standard care group, for which we have adjusted
in-group comparisons. Our data quality was high, with much lower attrition and fewer missing data
than would be expected in a palliative care trial of this scale. When planning the study, we set the
attrition rate at 17%, three times of that in our Phase II MS trial, to accommodate heterogeneities
across centres and conditions. The missing data for the primary outcome due to withdrawal or for
unknown reasons were 4% at 12 weeks. Although it is impossible to blind the participants and the
persons delivering the interventions, research nurses collecting the data were blinded, and the chief
investigators and analysis team were kept blinded until the planned analyses were completed. The
embedded qualitative component enables us to have a better understanding about the process, the
active ingredients and the mechanism of intervention.
We acknowledge that there are some limitations of this study. The sample largely comprised patients
with MS and IPD, who tend to have a longer disease course. This is also reflected in the embedded
qualitative study, which included mainly patients living with MS. It is possible that the baseline symptom
profiles and therefore the subsequent impact and experience of SIPC are different for patients with
LTNCs, with a more rapid decline. As mentioned above, the outcome measures used may not have
been sensitive enough and did demonstrate some floor effects at baseline for some symptoms. The cost
data were based on patient- (or carer-) reported use of services, which relies on their memory of the
services received. They may have under- or over-reported some services, and/or may have made some
miscategorisations, such as mistaking types of community care or palliative care. It is often difficult
for patients to correctly categorise the types of nurses or others visiting them in the community;
however, the mistaken categories in community home visiting services would have had little influence
on the overall costs. The main driver of costs was hospital admissions, which are less susceptible to
miscategorisation as non-admission.
Although every effort was made to standardise the intervention, and our fidelity data show that this
was, on the whole, well managed, there were some differences across centres, namely some intervention
teams were hospice based and others were hospital based, which led to differences in the make-up of
their MDTs, as well as the services and therapies they were able to offer. In addition, the clinical services
at baseline and the integration between palliative care and neurology varied across our centres and
across diseases. Some patients in the standard care arm reported that they were receiving palliative
care at baseline and, although this did not change during the study, this is because either they mistook
the research interviews for palliative care or there was contamination, which would have reduced the
chances of finding a difference between groups.
Implications
For clinical practice
Our findings have highlighted that patients with LTNCs and their caregivers have significant holistic
needs that are currently unmet. Our mapping work demonstrates significant heterogeneity and
variance nationally in the way that neurology and palliative care services are working, with several
instances in which there is silo working. In addition, there is variance nationally on access to palliative
care for different LTNCs. There are key areas in which further work can be taken forward by existing
services, to allow collaborative working and sharing of expertise. This includes training to explore
advance care planning and end-of-life care, and to facilitate joined-up working between all health
and social care systems to deliver optimal holistic care. Training is also required for neurology teams
to support comprehensive assessment of patients to best identify those who would benefit from a
referral to specialist palliative care services, and to ensure that needs (including social care needs)
are not overlooked and appropriate referrals are made.
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For policy-makers
Our findings suggest a need for further refinement of SIPC and the provision of holistic, palliative care
approaches for this patient group. We found that SIPC provides improvements in patient-reported
physical symptoms at a lower cost and without any harmful effects. Even patients in the standard care
group have perceived benefits of holistic care approaches through the comprehensive assessment of
their needs and concerns by research nurses. The SIPC intervention tested in this trial could be a
viable, potentially cost-saving and efficient care model valued by people severely affected by LTNCs.
The results from the mapping, survey and qualitative components highlight the urgent need to improve
integration between specialties to ensure the continuity of care so valued and desired by patients and
their caregivers.
Our findings, especially from the qualitative components, can be used to inform the refinement of
SIPC. First, SIPC would need to focus on physical well-being, including symptom management coupled
with supporting function, to promote independence, with emphasis on person-centred care and
accessible responsive services, especially at points of deterioration. Second, SIPC would need to be
able to provide and/or draw in psychosocial support, including mechanisms for adaptation and
resilience. Third, a focus on empowering and supporting lay caregivers through recognition and valuing
of their work, shared decision-making, and accessible services for advice and support. Easy and timely
access to practical support is important. Further research and secondary analysis could explore
whether or not any particular models of service (e.g. hospice, community or hospital based), team
composition or patient characteristics are associated with benefit.
For research
Our findings identify gaps that future research should focus on:
l The broader generalisibility of our research findings. It is necessary to evaluate how representative
the study sample is of the population the SIPC intended to target.
l Further testing and refining the triggers and criteria for referral to specialist palliative care for
patients with LTNCs.
l Research to improve symptom management in this population. The qualitative and quantitative
data suggested high levels of continuing symptoms that probably need better treatments to be
discovered so that care can be improved.
l Further development and refinement of generic outcome measures that can be used in both
research and clinical settings in people with LTNCs.
l Predictors of high-cost patients with LTNCs, given that we observed some considerable variation
in costs.
l How to monitor patients’ palliative care needs along their disease journey, and identify the right
timing for specialist palliative care and the right timing for boosting the intervention.
l How to implement holistic care approaches, such as SIPC, in wider neurology care settings.
l Establishing the evidence for longer-term effects of SIPC and determining how the effects change
over time, whether or not earlier referral to the palliative care affects the subsequent response to
palliative care, and when assessment or rereferral might be beneficial.
On the last point, data collected during the process of routine care, for example electronic health
records, have become valuable sources of data for research, as they bear the minimum data collection
burden on research participants. There have been an increasing number of applications of routine
data to enhance trial designs and facilitate trial implementation.98–100 Researchers should consider
exploiting the potential of routine data sources when addressing research questions, for example
those arising from this trial. These may be especially useful in exploring the longer-term effects on
health service use.
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Conclusions
To the best of our knowledge, this is the largest palliative care trial in people with a variety of LTNCs.
Although no significant between-group differences were seen, we have demonstrated that SIPC
provides improvements in patient-reported physical symptoms, at a lower cost and without any
harmful effects when compared with standard care. However, further work is needed to refine SIPC
and the provision of holistic, palliative care approaches for this patient group, with a particular focus
on better integration of existing services and specialties, as well as the appropriate timing and criteria
for the referral of LTNC patients to specialist palliative care.
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Appendix 1 Cumulative recruitment over the
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Appendix 2 Demographic and clinical
characteristics of patients with and without
primary outcome data
Variable Value Complete cases Missing
N 270 80
Age (years), mean (SD) 66.0 (11.6) 69.6 (11.8)
Gender, n (%) Man 137 (50.7) 42 (52.5)
Woman 133 (49.3) 38 (47.5)
Marital status, n (%) Single 28 (10.4) 7 (8.8)
Widowed 28 (10.4)) 10 (12.5)
Married/civil partner 182 (67.4) 49 (61.3)
Divorced/separated 31 (11.5) 13 (16.3)
Not done/unknown 1 (0.4) 1 (1.3)
Living status, n (%) Alone 53 (19.6) 12 (15.0)
With spouse/partner and/or children 188 (69.6) 56 (70.0)
With friend(s)/with others 29 (10.7) 12 (15.0)
Education, n (%) No formal education up to lower secondary school 103 (38.2) 36 (45.0)
Upper secondary to post-secondary vocational
qualification
95 (35.2) 21 (26.3)
Tertiary education 70 (25.9) 21 (26.3)
Not done/missing 2 (0.7) 2 (2.5)
Feelings towards
income, n (%)
Living comfortably on present income 87 (32.2) 31 (38.8)
Coping on present income 130 (48.2) 32 (40.0)
Difficult on present income 19 (7.0) 5 (6.3)
Very difficult on present income 12 (4.4) 2 (2.5)
Not done/unknown 22 (8.2) 10 (12.5)
Employment, n (%) No 262 (97.0) 78 (97.5)
Yes 8 (3.0) 2 (2.5)
Ethnicity, n (%) White 249 (92.2) 67 (83.8)
Other ethnic group 20 (7.4) 12 (15.0)
Not done/unknown 1 (0.4) 1 (1.3)
Comorbidities, n (%) No 76 (28.2) 23 (28.8)
Yes 194 (71.9) 57 (71.3)
AKPS, n (%) Totally bedfast 5 (1.9) 2 (2.5)
Almost completely bedfast 3 (1.1) 7 (8.8)
In bed > 50% of the time 11 (4.1) 10 (12.5)
Requires considerable assistance 127 (47.0) 43 (53.8)
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Variable Value Complete cases Missing
Requires occasional assistance 83 (30.7) 15 (18.8)
Cares for self 30 (11.1) 3 (3.8)
Normal activity with effort 9 (3.3) 0
Not available/applicable 1 (0.4) 0
Not done 1 (0.4) 0
Diagnosis, n (%) MS 121 (44.8) 27 (33.8)
IPD 104 (38..5) 36 (45.0)
MSA 10 (3.7) 2 (2.5)
PSPa 18 (6.7) 9 (11.3)
MND 17 (6.3) 6 (7.5)
Years since diagnosis 12.8 (10.8) 10.8 (9.7)
Mean (SD) 12.8 (10.8) 10.8 (9.7)
Patient capacity, n (%) Patient 270 (100) 41 (51.3)
Personal consultee 0 39 (48.8)
a Includes two corticobasal degeneration patients.
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Appendix 3 Additional health
economic analyses
To further show the uncertainty around the ICERs, we plotted the replications on thecost-effectiveness planes with 95% CIs (Figure 4).
To account for the joint uncertainty around the costs and outcomes, we calculated the probability of
SIPC being cost-effective compared with standard care, with reference to a set of maximum acceptable
ceiling ratios or WTP thresholds (λ). These probabilities were drawn as a cost-effectiveness acceptability
curve. The cost-effectiveness acceptability curves (Figure 5) show that SIPC was more cost-effective than





















































FIGURE 4 Cost-effectiveness planes of outcome measures (a) EQ-5D index score (QALY); and (b) rescaled IPOS Neuro-S8,
and health and social care cost with 95% CIs.
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The INMB of SIPC and standard care at a range of WTP thresholds, was generated using Equation 2,
in which λ is a given WTP threshold. The INMB of SIPC relative to standard care at various WTP
thresholds was plotted:
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FIGURE 5 Cost-effectiveness acceptability curves of SIPC compared with standard care, using outcome measures
(a) EQ-5D index score/QALY; and (b) rescaled IPOS Neuro-S8, and health and social care cost.
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The INMB of SIPC compared with standard care was positive (Figure 6), with wider 95% CIs as the
WTP threshold became larger. The INMB of SIPC using IPOS Neuro-S8 needs to be interpreted with
caution, as there has been no agreement on the WTP for 1 unit of the measurement.
Overall, these further analyses are consistent with the findings from the main analysis. The INMB
obtained can be used to present the benefit of SIPC compared with standard care as a monetary
benefit from the intervention.
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FIGURE 6 Incremental net monetary benefit of SIPC compared with standard care, using outcomes (a) EQ-5D index
score/QALY; and (b) rescaled IPOS Neuro-S8, and health and social care cost.
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Appendix 4 Caregiver demographics for
qualitative interview participants
Variable Value Interviewed caregivers (N= 16)
Age (years), mean (SD) 58.9 (14.7)
Gender, n (%) Man 6 (37.5)
Woman 10 (62.5)
Relationship to patient, n (%) Spouse/partner 11 (68.8)
Son/daughter 3 (18.8)
Other 2 (12.5)
Ethnicity, n (%) White 15 (93.7)
Other ethnic group 1 (6.3)
Employment, n (%) No 10 (62.5)
Yes 6 (37.5)
Illness, n (%) No 7 (43.8)
Yes 9 (56.2)
Baseline ZBI-12
Mean (SD) 20.9 (9.5)
Range 0–41
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Appendix 5 Analytical framework on the
value and impact of short-term integrated
palliative care
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Theme/definition Subcategory Definition Illustrative quotation
Adapting to losses and building
resilience: key strategies for
adjusting to increasing disability,
declining function and nearness to
end of life
Care beyond medicines Psychosocial interventions of skilled support,
valuing and appreciating what life is like, and
practical support. Psychosocial interventions
were valued to support resilience and
adaptation, and counter feelings of loneliness
However, with increasing complexity of
psychosocial needs and the short-term nature
of the intervention limited opportunity to build
sufficient trust and rapport to enable patients
and caregivers to engage in difficult
conversations
We [the palliative care nurse and I] did talk
about it [feeling lonely and down sometimes].
MS can be very frightening and lonely and you
know I’m grieving for my body and the life I
had. I know this is still my house, but it doesn’t
feel like my house anymore. I do get quite down
sometimes and then I think who can I talk to
but then I use meditation to help me with that
and to stay positive. I did see a counsellor
many years ago and that was helpful so maybe
that is something I should have asked for [from
the palliative care nurse]
Patient P01348-F
Asked about everything Planning future care for end-of-life experiences,
expectations and impact
Engagement ranged from ‘not all’ to ‘I’ve been
writing stuff down for years’
Engagement was marked by uncertainty in ‘not
knowing what’s going to take hold’ and fear of
increasing disability and loss of capacity
The SIPC intervention seemed to be the start
of a conversation
. . . she [the palliative care nurse] did say ‘Have
you thought about the future?’ and what your
plans are for the future and stuff like that. I
mean, I know that a lot people do recommend
that you make plans and you think about
what’s gonna happen when she becomes more
dependent. Errm you know, how you’re gonna
cope as a family, what kind of errm, what
you’re gonna do really. I’m really of the thought
that you can’t really plan too much when it
comes to something like MS, dementia because
you just don’t know when things are gonna

































Theme/definition Subcategory Definition Illustrative quotation
Attend to function, deficits and
maintaining stability: optimising
function and independence, and
managing physical deficits and
concerns
Little things that make a big difference
P0139-M
Optimal management of unstable symptoms to
reduce distress (e.g. breathlessness, pain)
Key components for impact:
l Understanding complexity of symptom
distress, ‘quick fixes’ were rare
l Symptoms complex or refractory, or change
in medication worsening other symptoms
l Availability of skilled practitioners ‘to know
people are available and willing to try and
improve symptom management’
l Working with the person and caregivers to
support management approaches honed
over time and prevent duplicating previously
unsuccessful interventions (e.g. medication
for depression)
l Integrated working with neurology services
to manage optimally medication
l Timely response to unstable symptoms and
concerns to prevent ‘domino effect of
decline’
Maintaining function and independence by
supporting adaptation and problem-solving
(e.g. continence, mobility, falls prevention,
eating and drinking)
Key components were:
l Involvement of the MDT (OT to support
function, physiotherapy and complementary
therapies to provide non-pharmacological
interventions
Lack of attention to function an area of
frustration for patients and carers
Well it’s [emotional concerns] sort of linked to
my physical feelings really so I didn’t feel like I
was ever gonna improve but I have begun to
improve. I’m feeling a bit ill and fluey and that
sort of winter feeling at the moment, but the
massage [SIPC therapist] was the start I think
of me feeling better, and getting more sleep and
feeling more generally well in myself. So it’s a
subtle change in some ways but in some ways
it’s quite a large thing cos just going to bed was
a nightmare, I just couldn’t sleep at all and it
was making me more tired and it seemed to
make the symptoms worse in the morning and
during the day and so I think it’s a good thing
that I can actually go to bed and just sleep
again since being on this course [of massage
and change to medication for spasm]
Patient P05182-M
Well when I discussed my incontinence [with
palliative care Clinical Nurse Specialist], which
is difficult to discuss with a guy [my husband],
it’s nice to talk to a lady about that sort of
thing, I find that very helpful. She gave me
some nice pointers as to what to do and how
to overcome certain things which was very
good you know because in the end though he
does a lot for me, I love him [husband] but you
can’t talk about some certain things, it’s too














































































































































































































































































































































Theme/definition Subcategory Definition Illustrative quotation
Maintain stability Although living with extensive losses and
deficits, individuals considered themselves
‘stable’ and as working continuously to
maintain stability
SIPC is about skilled support, by increasing
awareness and understanding of management
of symptoms and concerns. For some, there
was no impact from involvement of SIPC. No
difference felt from symptoms and concerns as
used to living with them and equipment already
in place to maintain independence
Errm wouldn’t say make a difference but she
[palliative care nurse], she you know explained
errm certain things how things would be helped
in certain ways and that. Errm . . . well just
really just sort of [pause] like with his errm
bowel movement and that to give you know, if
it’s really bad, giving him Imodium [loperamide]
every now and again which could possibly help
Caregiver C05275-F
Enabling carers to care:
empowering carers
Enabling carers to care Recognising the role of caregivers, valuing and
acknowledging their work
Complexity of caring with a tendency to put the
person before themselves
Not asking for help, but also frustrated when
their needs are not considered
Supporting caregivers from simple intervention
of acknowledging and valuing, through to
complex ongoing process requiring continuity
of care
Whilst I don’t think errm, there’s not really a lot
that she can do for me errm, that I can think of
because I tend to sort of manage, you know. I
manage as best I know how, you know errm,
but I think it’s the fact that she’s, her intervention,
you know, irrespective of what she was or wasn’t
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